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CHAPTER 1 INTRODUCTION
GWAS and functional genomics: uncovering the molecular mechanisms behind asso-
ciation
Genome wide association studies (GWAS) have identified thousands of common ge-
netic variants associated with complex traits, including normal traits and common dis-
eases. For these studies, case and control individuals are genotyped, then differences in
allele frequency at each single nucleotide polymorphism (SNP) are quantified. SNPs are
determined to be associated with the trait if the case allele frequency is significantly dif-
ferent from that of the control group (Figure 1A). The end goal is to discover the genetic
basis of complex traits in order to predict case conditions, for intervention, and for ther-
apeutics. GWAS work by exploiting linkage disequilibrium (LD), with genotyping arrays
sampling just enough SNPs to determine haplotype. These haplotypes are a result of histor-
ical evolutionary forces such as population size, mutation, recombination rate, and natural
selection.
Despite many successful findings, GWAS have failed to explain the majority of esti-
mated heritability. Part of this problem comes from the fact that GWAS identify large
regions of association and in general, cannot directly pinpoint the true causative variant.
Statistical power is an additional challenge. In order for a variant to reach genome-wide
significance, it depends on sample size, effect size of the causal variant, and frequency
of the variant. Despite the challenges, array style studies remain the most common due
to how affordable they are. Unobserved variant frequencies can typically be recovered
through statistical imputation by using haplotype information, therefore increasing statis-
tical power for the study.
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Figure 1: GWAS study outline and example hit. Source: Wellcome Trust Case Control Consortium (June 2007). A) Overview of GWAS
study design. B) GWAS hit for Crohn′s Disease.
The success and failure of GWAS have spurred multiple approaches to better model
population structure, identify novel variants, estimate and partition genetic covariance, or
infer causality. One of the largest challenges that faces GWAS is in determining the func-
tional relevance of human DNA sequence variants (Ward and Kellis, 2012). An estimated
80% of the genome (Consortium, 2012), and an ever larger percentage ( 90%) of GWAS
hits (Maurano et al., 2012), lie outside of protein coding regions. This makes it difficult
to infer mechanisms linking individual genetic variants with the disease trait (Figure 1B).
In addition, we do not know under which environmental conditions the sequence vari-
ants have a functional impact, and whether they become one of many factors involved in
complex phenotypes at the organismal level.
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High-throughput assays to identify functional regulatory variants
Non-coding regions in the genome are largely made up of regulatory elements, for
which it can be difficult to predict the functional outcome of variants within these sites.
Functional genomics data collected by ENCODE (http://genome.ucsc.edu/ENCODE/), Roadmap
Epigenome (http://www.roadmapepigenomics.org/), and other groups (Visel et al., 2009)
have provided large amounts of information on regulatory regions of the human genome
(Figure 2A). Protein binding to DNA mainly controls gene regulation and these proteins
require open chromatin to access the DNA. DNA accessibility assays (e.g., DNase-seq (Song
and Crawford, 2010), FAIRE-seq (Simon et al., 2012) or ATAC-seq (Buenrostro et al.,
2013)) are used to identify these regions. DNase-seq uses an enzyme, DNaseI to cut DNA,
where it can′t cut heterochromatin or regions bound by a protein (protected areas). The
DNA is sequenced, and regions of open chromatin show peaks of increased cuts. However,
even with identifying accessible regions this fails to provide regulatory mechanisms.
Transcription factors (TFs) are important gene regulators and include both enhancers
and repressors or insulators. Enhancers are short DNA regions of 20-400bp that can acti-
vate promoters (Bondarenko et al., 2003) to increase gene expression. They work by sta-
bilizing DNA-protein complexes at the enhancer and target promoter before activation or
forming loops to bring the enhancer and the promoter closer together, facilitating commu-
nication between the enhancer and its target (Bondarenko et al., 2003; Ong and Corces,
2011; Krivega and Dean, 2012). Enhancers are well characterized as working position
independent, and can target promoters both in cis and in trans. In contrast, insulators typ-
ically work by separating enhancers from the target promoter, creating separate domains.
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Loop formation is the most common mechanism, and this is typically orientation depen-
dent, needing the insulator and promoter in anti-parallel directions (West et al., 2002).
A
B C
Figure 2: High-throughput regulatory assays. Non-coding regulatory DNA in the human genome. Source: Elkon and Agami (2017).
B) NRSF peak and motif from Centipede. Source: Moyerbrailean et al. (2016b). C) EMSA overview. Source: Gibiansky (2015).
Chromatin immunoprecipitation sequencing (ChIP-seq) assays can directly identify where
TFs are binding genome-wide, where the DNA-bound protein is immunoprecipitated using
a specific antibody. There are some drawbacks to this method. While this method does
capture genome wide binding, it is only for a single TF at a time, making this method low
throughput. This method also relies on the availability of high quality antibodies to the TF
of interest. Also, recent studies have found that 50% of the binding sites found may have
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no role in transcriptional regulation (Li et al., 2008; Fisher et al., 2012; Teytelman et al.,
2013; Lizio et al., 2015). This may be due to non-specific binding of TFs to the DNA, which
allows for transient binding for non-functional weak interactions (Shlyueva et al., 2014).
Alternatively, binding events can be identified from DNase-seq data, which allows for
identification of all potential TFs from a single assay. Centipede (Pique-Regi et al., 2011) is
a program that detects these sites by integrating binding sites predicted by a motif model
with genome wide DNase I footprinting data (from the ENCODE and Roadmap Epigenome
projects). Transcription factors bind in regions where the chromatin is open and is more
accessible to DNase I cleavage. To identify these sites, peak sites are analyzed for footprints
of protection from DNase which is likely where the TF is binding. Looking at the DNA
sequence at this position can provide the motif for the TF binding there (Figure 2B).
The availability of extensive functional annotations (Consortium, 2012; Pique-Regi
et al., 2011; Hoffman et al., 2012) now enables the integration of functional genomic in-
formation into eQTL and GWAS analysis, which can be useful to dissect the causal variant
and the functional basis of the observed associations. SNPs that fall within a transcription
factor binding site represent a major mechanism underlying gene expression quantitative
trait loci (eQTL) and GWAS variants are also much more likely to be expression quanti-
tative trait loci (eQTNs) than SNPs not associated with any complex trait. (Nicolae et al
2010; Zhong et al. 2010). Linking genomic annotations to eQTLs and GWAS SNPs goes
beyond genetic association analysis, and helps gain a better understanding of the underly-
ing biological processes. Some of these issues have been discussed by previous works. For
example, (Gaffney 2012, Veyrieras 2008, Lee 2009, Lappalainen 2013) have examined the
enrichment of selected genomic annotations in cis-eQTLs, and (Pickrell 2014; Price 2012)
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have found enrichment for functional categories in GWAS hits. In addition to predicting
causal SNPs associated with GWAS traits within regulatory regions, it is possible to predict
the allele specific binding (ASB) effect of any SNP within a motif, but this does not predict
whether binding enhances or represses gene expression.
High-throughput assays to identify functional regulatory variants
There are a few methods that have been used to experimentally test for ASB. The two
most common are QTL mapping and allele specific analysis. For QTL studies, large panels
of individuals are genotyped, and the genotype is then matched to a quantitative trait (ie.
open chromatin (dsQTL), gene expression (eQTL)). For higher throughput, allele-specific
analysis can be used, where in a single individual you see the difference in allele count
within the reads. However, these require heterozygous sites and in-depth sequencing to
analyze.
Electrophoretic mobility shift assay (EMSA) can can identify TF binding to any DNA
sequence of interest. For this, the DNA sequence is combined in-vitro with the TF of interest
and then run on a polyacrylamide gel. Where the protein binds, the complex travels more
slowly through the gel, so the bound portion of DNA can be seen shifted upwards from the
free or unbound DNA. The EMSA however, is more qualitative than quantitative, as well
as being low throughput testing a single sequence at a time. This led to the development
of the high throughput EMSA (Wong et al., 2011; Stormo et al., 2015; Levo et al., 2015),
where a pool of sequences are combined with the TF of interest, the bound and unbound
portions of the gel are cut out, DNA extracted and sequenced to get a quantitative measure
of the binding events (Figure 2). While BUNDLE-seq compared binding and reporter gene
expression, and EMSA has been previously used to ascertain allelic effects, none of the
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high-throughput EMSA methods have been previously used to determine allelic effects on
binding.
Identifying ASB is necessary for assigning mechanism to expression and phenotype
outcomes. However, gene regulation is highly complex, so binding changes do not always
lead to a predicted outcome. Instead, effect on expression can be measured, and the gold
standard for this is the traditional reporter assay. For this, the enhancer region containing
either allele is cloned into a plasmid containing a minimal promoter and reporter gene
(typically luciferase). This gets transfected into cells, and readout (luminescence) is a
measure of the enhancer strength. However this method is both time and cost intensive
to test each construct one at a time. So in the last few years, high throughput methods
were developed to test the expression of thousands of oligos at once. There are two main
methods for this, the massively parallel reporter assay (MPRA) and self transcribing active
regulatory sequencing (STARR-seq). For MPRA (Melnikov et al., 2012; Kwasnieski et al.,
2012; Patwardhan et al., 2012; Sharon et al., 2012; Kwasnieski et al., 2014), a multitude
of unique synthesized DNA oligos containing a barcode at the 3′ UTR of a reporter plasmid
are transfected into cells, and transcripts are isolated for RNA-seq. The number of barcode
reads in the RNA over the number of barcode reads from the plasmid DNA is used as
a quantitative measure of expression driven by the synthesized enhancer region. This
method is fairly complex, requiring sequencing after cloning the enhancer/BC into the
plasmid to match the sequences together and then another cloning and sequencing to place
the reporter gene between the enhancer and BC. While the oligo being matched to multiple
BCs helps with noise, it is imperfect since so many steps lie between the matching step and
the final libraries. Studies have used this method to broadly characterize mutations within
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enhancer and repressor regions (Melnikov et al., 2012; Kwasnieski et al., 2014) and fine-
map eQTLs (Tewhey et al., 2016) or GWAS (Ulirsch et al., 2016).
STARR-seq (Arnold et al., 2013) methods involve fragmenting the genome and cloning
the fragments 3′ of the reporter gene and sequencing the fragment directly instead of a BC
proxy. The approach is based on the concept that enhancers can function independently
of their relative positions and it′s designed with putative enhancers placed downstream of
a minimal promoter, such that active enhancers transcribe themselves, with their strength
quantified as the amount of RNA transcripts within the cell. Because they do not use
separate barcodes, STARR-seq approaches have streamlined protocols that allow for higher
throughput. However, due to the lack of barcoding, these studies tend to be noisy.
In the original study, the D. melanogaster genome was fragmented and transfected into
S2 cells (Arnold et al., 2013). An additional study involved treating transfected S2 cells
containing the STARR-seq library with ecdysone (Shlyueva et al., 2014) (a well-studied
hormone in insects) as many enhancers are controlled by external stimuli (Hurtado et al.,
2011; Biddie et al., 2011; Hah et al., 2011, 2013; Shlyueva et al., 2014). A more recent
adaptation to this method is Cap-STARR-seq (Vanhille et al., 2015). This method targeted
specific regulatory regions whereby DNA fragments were captured on a custom-designed
microarray. These methods were created to identify and validate regulatory regions, with
no consideration of regulatory variants. However, placing the variant in biological con-
text, for example by identifying the transcription factor whose binding is disrupted, often
improves our understanding of disease mechanisms and opens further avenues for thera-
peutic intervention.
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Analysis of the molecular function of non-coding variants across diverse risk envi-
ronments
Aside from epidemiological studies, little attention has been paid so far in understand-
ing how an individual′s genetic make-up interacts with his/her environmental exposures in
defining disease risk. Accordingly, it is crucial to consider the role of genetic risk factors in
the context of specific environments (e.g. vascular endothelium and stress for CVD-related
traits). Little attention has focused on the analysis of how gene-environment interactions
may affect an individual′s phenotype, because, in part, controlling for an individual′s life-
time environment is difficult. Cowper-Sal-lari et al. 2012 (Cowper-Sal et al., 2012) used
functional genomics data to functionally annotate GWAS hits for breast cancer variants,
by using functional genomic assays in the context of in-vitro estrogen treatments. The
success of this study resides in considering the specific environmental context (estrogen
treatment) relevant for the complex trait analyzed (breast cancer). These findings further
support the necessity of considering the molecular function of each genetic risk variant in
the context of the cellular and the organismal environment.
While it is extremely difficult to control for environmental exposure in the context of
GWAS studies, they can be modeled under in-vitro settings with the cellular environment as
a proxy for the organismal environment. This has been successfully done in eQTL studies
looking at response to infection (Nédélec et al., 2016; Pacis et al., 2015) and drug treat-
ment (Maranville et al., 2011; Mangravite et al., 2013; Maranville et al., 2013), known as
reQTLs. Looking at response to treatments with this method however is not viable on a
large scale. Instead it is possible to use an allele-specific approach, where allelic effects are
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modeled within a single individual at heterozygous sites. This method is also more con-
trolled for confounding factors, giving it more power to detect conditional ASE (cASE) than
is possible in reQTL studies, particularly in small sample sizes. For even more controlled
conditions, exact sequences can be studied in the case of high throughput reporter as-
says, as was done in S2 cells with ecdysone (a well-studied hormone in insects) (Shlyueva
et al., 2014) and A549 cells with dexamethasone (synthetic glucocorticoid) (Vockley et al.,
2016).
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CHAPTER 2 Computational predictions and analysis of non-coding
variants for allele-specific expression 1
Introduction
Genetic variants in non-coding regions are responsible for inter-individual differences
in molecular and complex phenotypes. Quantitative trait loci (QTLs) for molecular and
cellular phenotypes (Dermitzakis, 2012) have been crucial in providing stronger evidence
and a better understanding of how genetic variants in regulatory sequences can affect gene
expression levels (Stranger, 2007; Gibbs et al., 2010; Melzer et al., 2008; Cheung et al.,
2003; Brem et al., 2002). However, eQTL studies have severe limitations in identifying the
true causal variant, due to linkage disequilibrium (LD) limiting the resolution of analysis.
The availability of extensive functional annotations (Consortium, 2012; Pique-Regi et al.,
2011; Hoffman et al., 2012; Moyerbrailean et al., 2016b) enables the integration of func-
tional genomic information into eQTL analysis, which can be useful to dissect the causal
variant and the functional basis of the observed associations (Gaffney et al., 2012; Veyri-
eras et al., 2008; Lee et al., 2009; Lappalainen et al., 2013; Kichaev et al., 2014; Wen et al.,
2015; Pickrell, 2014). SNPs that fall within a transcription factor (TF) binding site (TFBS)
represent a major mechanism underlying eQTLs (Degner et al., 2012). Recently, additional
computational and experimental techniques have been developed to predict and detect al-
lelic effects of SNPs in TFBS (CentiSNPs) using DNase I footprinting and ChIP-seq data
(from the ENCODE and Roadmap Epigenome projects) (Moyerbrailean et al., 2016b; Lee
et al., 2015a; Maurano et al., 2015; Zhou and Troyanskaya, 2015). Still, it is a challenge
1Parts of this chapter originally appeared as: Moyerbrailean, G. A., Kalita, C. A., Harvey, C. T., Wen, X.,
Luca, F., & Pique-Regi, R. (2016). Which Genetics Variants in DNase-Seq Footprints Are More Likely to Alter
Binding? PLoS Genetics, 12(2), e1005875.
Kalita, C. A., Moyerbrailean, G. A., Brown, C., Wen, X., Luca, F., & Pique-Regi, R. (2018). QuASAR-MPRA:
Accurate allele-specific analysis for massively parallel reporter assays. Bioinformatics, 34(5).
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to further validate if allelic effects in binding translate to effects on gene transcription.
Here we used the CentiSNPs annotation (variants predicted to affect TFBS) generated
from previous work in done in the lab (Moyerbrailean et al., 2016b) in combination with
a software called fgwas (Pickrell, 2014) to finemap variants associated with GWAS. The
rich meta information provided by the tissue-specificity and the identity of the putative TF
binding site being affected also helps in identifying the underlying mechanism supporting
the association. While all these existing computational annotations are useful for predict-
ing the causal SNP in an eQTL, they do not prove the SNP is truly causal, nor do they
properly quantify its effect on gene expression. This can be validated experimentally using
a traditional reporter assay, where the enhancer region is cloned into a plasmid containing
a minimal promoter and reporter gene (ie. Luciferase. This gets transfected into cells,
then the reporter signal is used as a correlate of the enhancer activity. Here we tested a
subset (21) of the putatively causal GWAS hits identified using fgwas with the CentiSNP
annotation for significant allele specific gene expression.
Traditional reporter assays, while the gold standard for the field, are both time and
cost intensive. Instead, to dissect regulatory sequences and compare genetic effects on
gene expression, different versions of high throughput reporter assays have emerged in
the recent years. These include massively parallel reporter assays (MPRA) (Melnikov et al.,
2012; Kwasnieski et al., 2012) and self transcribing active regulatory regions sequencing
(STARR-seq) (Arnold et al., 2013) that can simultaneously measure the regulatory function
of thousands of constructs at once. MPRAs utilize a multitude of unique synthesized DNA
oligos that are associated with barcodes, cloned in a reporter plasmid and transfected into
cells. The transcripts are then isolated for RNA-seq. The number of barcode reads in the
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RNA over the number of barcode reads from the plasmid DNA is used as a quantitative
measure of expression driven by the synthetic enhancer region (Melnikov et al., 2012;
Kwasnieski et al., 2012; Patwardhan et al., 2012; Sharon et al., 2012; Kwasnieski et al.,
2014). MPRA and STARR-seq were originally developed to identify and validate regulatory
regions, but they can also be used to compare allelic effects of genetic polymorphisms
or methylation (Lea et al., 2017). Recent studies used this technique to compare allelic
variants of SNPs with the aim to dissect, at a large scale, the causal nucleotide in eQTL
and Genome Wide Association Study (GWAS) signals. Specifically, Vockley et al. (2015)
used a STARR-seq derived method (POP-STARR-seq) to measure allelic effects on gene
expression for population based variation in 104 regulatory regions, and a more recent
study by Tewhey et al. (2016) adapted MPRA to fine-map variants associated with gene
expression in lymphoblastoid cell lines (LCLs) and HepG2.
The application of MPRA to quantify the allelic effects of regulatory variants is very
similar to the challenge posed by allele-specific expression (ASE) in RNA-seq data. How-
ever, one key difference is that the proportion of plasmids for each allelic construct may
not be in a 1:1 ratio. Few off-the-shelf statistical methods have been used for processing
and analyzing these large MPRA datasets (Table 1), but they do not consider several tech-
nical issues that can lead to false positives, such as base-calling error and over-dispersion.
As demonstrated in RNA-seq ASE approaches, a binomial distribution fails to account for
overdispersion and results in overly optimistic p-values, while a beta-binomial distribution
is a more adequate choice (Kumasaka et al., 2016; van de Geijn et al., 2015). Compared
to RNA-seq ASE methods that combine all reads across haplotypes, in MPRA we do not
need to accommodate for the uncertainty in phasing or haplotyping as the complete se-
14
Table 1: Statistical methods for ASE and MPRA analysis.
Type of test
Conditions T Fisher Bin β-bin QuASAR
Previously used in MPRA X X
Previously used for ASE X X X
Requires normally distributed data X
Underestimates the effect of biological variability X X X
Handles overdispersion X X
Accounts for base calling error X
quence of each construct is known. By design we can also avoid oligonucleotides that
could lead to ambiguous mapping. This is in stark contrast to using the entire human
genome/transcriptome, which typically requires extensive pre-processing. This is because
many genomes contain large number of repetitive and quasi-repetitive regions that are
only one SNP or base-calling error away from many other paralogous regions. Here we
further extend QuASAR (Harvey et al., 2014), an approach which considers both over-
dispersion and base-calling errors, to test for allelic imbalance in MPRA constructs when
the default proportions are not equal. The new method allows for estimates of the dis-
persion parameter depending on variant-specific read coverage, and produces summary
statistics that are easy to incorporate in downstream analyses.
Here we tested our new method on MPRA data from Tewhey et al. (2016) and we fur-
ther confirmed the robustness of our method on another dataset from Ulirsch et al. (2016).
First we compared our new QuASAR-MPRA statistical test to other tests employed in MPRA
and ASE analyses (Table 1). We then demonstrate that the QuASAR-MPRA test better cali-
brates the p-values under the null hypothesis, without sacrificing statistical power. Finally,
we used the allelic effects identified by QuASAR-MPRA to investigate whether the genetic
variants that fall within genomic annotations, such as TF binding motifs, are good predic-
tors for allele-specific regulatory function. Our study shows the potential value of using
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robust allele-specific analysis in high throughput reporter assays, to improve fine mapping
analysis of association signals and validate genomic annotations of regulatory variants.
Methods
Integrating high-resolution functional annotations with GWAS and fine-mapping
To integrate functional annotations and GWAS results, we used the fgwas command
line tool (Pickrell, 2014). fgwas computes association statistics genome wide using all
common SNPs from European populations in the 1KG Project, splitting the genome into
blocks larger than LD. Summary statistics were imputed with ImpG using Z-scores from
meta-analysis data. Using an empirical Bayesian framework implemented in the fgwas
software, GWAS data were then combined with functional annotations. We then com-
pared the informativeness of these annotations from each of the 1891 motifs with Cen-
tipede predicted regulatory sites to a baseline model (see section: Adding annotations to
SNPs associated with complex traits in Appendix A) consisting of previously used genomic
annotations identified as relevant (Pickrell, 2014). For each locus that contains at least
one SNP with a PPA > 0.2, we only consider the SNP with the highest p-value or PPA from
fgwas. Rather than look at a credible set, we pick a single SNP most likely to be causal and
see if that SNP has a higher PPA with the annotation than without it. While reduction in
size of the credible set is very important for assessing fine-mapping methodologies, here
our focus is on combining annotations to identify the single most likely causal SNP per
GWAS locus.
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Validation of GWAS-relevant effect-SNPs
GWAS-relevant effect-SNPs located in active footprints in LCLs (the cell line used for
transfection) were ranked on the Spearman correlation coefficient in Moyerbrailean et al.
(2016a). We initially selected the top 25 SNPs with a positive correlation, but the as-
says for 4 of them failed for several technical reasons (e.g., cloning step failed). To test
allele-specific effects on expression for the remaining 21 SNPs, we first constructed inserts
containing the reference or alternate allele for each SNP of interest (see section: Validating
putative causal SNPs by reporter gene assays in Appendix A). Cloning of these inserts in the
pGL4.23 vector was performed using the Infusion Cloning HD kit (Clontech) and DNA was
extracted using the PureYield kit (Promega). Transfections were performed into GM18507
using the standard protocol for the Nucleofector electroporation (Lonza). Luciferase activ-
ity was measured for up to 20 replicate experiments using the Dual-Glo Luciferase Assay
Kit (Promega). We contrasted the activity of each construct to the pGL4.23 vector, to
assess enhancer/repressor activity of each region. To evaluate allele-specific effects, we
contrasted the activity of the reference allele to the alternate allele for each region and
we used a t-test to assess significance at a p < 0.05 threshold. We used the Benjamini-
Hochberg (Benjamini and Hochberg, 1995) procedure to assess FDR across all 21 SNPs
tested.
Data source and pre-processing
We downloaded processed read counts from GEO (GSE75661) ftp://ftp.ncbi.nlm.
nih.gov/geo/series/GSE75nnn/GSE75661/suppl/GSE75661_79k_collapsed_counts.txt.
gz (Tewhey et al., 2016). This MPRA study was designed to look at ASE in 39,479 oligo
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pairs representing 3,642 eQTLs from the GEUVADIS RNA-seq dataset of lymphoblastoid
cell lines (LCLs) from European and African individuals (Lappalainen et al., 2013). It has
a large number of experimental replicates (8 LCL replicates), and makes use of barcodes
(an average of 73 unique barcodes per oligo per replicate) to remove PCR duplicates,
making this an ideal dataset to work with. We considered separately sequences in the for-
ward and reverse strand direction in the library, as direction of the regulatory region could
potentially affect reporter gene and therefore barcode expression. Tewhey et al. (2016)
found that filtering the data to remove variants with low coverage greatly reduced the
variability between replicates. Higher variance could then lead to falsely identifying ASE.
We therefore began processing the dataset by applying a counts filter. For each direction
we removed all cases with less than five reads on the reference and alternate allele, and
where the sum of two alleles was ≤ 100. This gave us a total of 33,664 SNPs in the DNA
library as input to the RNA library.
For the RNA library, we first separated the library into forward and reverse directions,
and then required that RNA constructs were in the DNA library. We used a counts filter of
5 for both reference and alternate alleles so that we were only looking at variants that had
sufficient reads covering both alleles to test for allele-specific effects on expression. This
left us with 19,287 SNPs in the forward library and 19,748 SNPs in the reverse library or
33,653 SNPs total represented.
We additionally applied the QuASAR-MPRA method to a separate dataset by Ulirsch
et al. (2016). We downloaded processed read counts from http://www.bloodgenes.org/
RBC_MPRA/. This dataset comprised of 2,756 variants in strong linkage disequilibrium with
75 sentinel variants associated with red blood cell traits, with reference and alternate alle-
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les represented in the pool of constructs. Each variant has 3 sliding windows of coverage,
which we treated as separate constructs (rather than combining counts per variant). This
dataset comprised of 2 DNA and 6 RNA replicates (from K562 cells). The data was pro-
cessed using the same steps as with the Tewhey et al. (2016) data, resulting in 2,669 SNPs
in total.
Baseline statistical methods for comparison
To test for ASE there are several different methods available (Table 1). The t-test,
Fisher′s exact test and binomial test are classical tests remarkably appealing due to their
simplicity. However, they have several limitations, as they cannot be tuned to the context
of the experiment, such as levels of overdispersion (eg. from biological and technical
variability) which are known to exist in ASE data (Castel et al., 2015; Skelly et al., 2011;
Anders et al., 2010). A paired Student′s t-test for ASE can be used to test whether the
mean expression of the reference allele is equal to the mean expression of the alternate
allele. This test requires multiple replicates in order to calculate a mean for each allelic
expression group that has little variance, otherwise the test will not have the power to
detect differences. Fisher′s exact test has been used previously to identify ASE (Romanel
et al., 2015), by testing whether the reference and alternate allele counts′ proportions are
the same. Rejection of the null hypothesis, however, only informs us that the difference
between the average counts in the two samples is larger than one would expect between
technical replicates. In the binomial test, the null hypothesis is that observed values for
two categories do not deviate from the theoretically expected distribution of observations.
In ASE, the binomial test is used to determine whether the ratio of the two alleles is
significantly different from the expected proportion (e.g. 0.5). This is the classic test that
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has been employed previously to detect ASE in RNA-seq studies, and assumes that read
counts within each gene are binomially distributed (Kilpinen et al., 2013; Consortium et al.,
2015; Lappalainen et al., 2013; Buil et al., 2014). Even accounting for reference mapping
bias in RNA-seq reads, p-values have been found to remain inflated (Castel et al., 2015).
Other methods handling ASE such as WASP, RASQUAL, EAGLE (Kumasaka et al., 2016;
van de Geijn et al., 2014; Knowles et al., 2017) use a per SNP overdispersion parameter
and give well calibrated p-values. However these methods perform ASE QTL mapping and
their application to MPRA would require a large number of replicates (> 15).
To reproduce the Student′s t-test performed by Tewhey et al. (2016), we calculated the
log2 ratio for the reference and alternate allele constructs (RNA/DNA) for each replicate.
These values were used as input for a paired t-test in R. To perform the Fisher′s exact test
on the MPRA counts data, we first added a pseudocount of 1 (Vockley et al., 2015) to
each RNA and DNA reference and alternate allele counts and then used the fisher.test
function in R. To perform the binomial test on the MPRA counts data, we compared the
reference and alternate allele counts to the DNA proportion (reference allele/ reference
allele + alternate allele). To combine the p-values for the two LCL individuals, we used
Fisher′s method (Tewhey et al., 2016).
QuASAR Approach
QuASAR by default assumes that under the null hypothesis of no allelic imbalance the
reference and alternate allele read counts should be at 1:1 ratio. However, in MPRA, the
proportion rl of the reference reads is not necessarily 0.5 across all the l genetic variants,
due to differences in PCR amplification, as well as cloning and transformation efficiencies.
Here, we have extended QuASAR to test for differences between the proportion of refer-
20
ence reads in DNA rl and the proportion obtained from RNA reads ρl. To reject the null
hypothesis ρl = rl, we extend QuASAR′s beta-binomial model. The observed reference Rl
and alternate Al allele read counts at a given l are modeled as:
Pr (Rl|Nl, ψl,Mb) =(
Nl
Rl
)
Γ (Mb) Γ (Rl + ψlMb) Γ (Al + (1− ψl)Mb)
Γ (Nl +Mb) Γ (ψlMb) Γ ((1− ψl)Mb)
(0.1)
ψl = [ρl(1− ε) + (1− ρl)ε] (0.2)
where Nl = Rl + Al is the total read count at l, and Mb is the concentration parameter
that controls over-dispersion of the mean proportion centered around ψl, which also in-
corporates in the model a base-calling error ε and the allelic ratio ρl overall-mean. We
can estimate ε using an EM procedure (Harvey et al., 2014), but here for MPRA we fixed
ε̂ = 0.001 as a conservative estimate of the true base-calling error rate.
We have found previously for ASE that overdispersion decreases with greater depth of
coverage (Figure S9 in Moyerbrailean et al. (2016a)). Therefore here, as compared to our
previous implementation of QuASAR, we use different Mb parameters depending on the
sequencing depth Nl. We bin Nl into different quantiles (here deciles) and we estimate Mb
for each bin separately using a grid search:
M̂b = arg max
Mb
(
L∏
l=1
Pr (Rl|Nl, ε̂, ρl = rl,Mb)
)
(0.3)
This should work well when the number of sites (i.e., SNPs tested) is relatively large so
each bin b has > 200 observations to estimate Mb. In our experience sequencing depth
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is a major determinant for M, and because we estimate M under the null, we tend to be
conservative (i.e., M is the worst case scenario for all the constructs that belong to the
same group). As a consequence, the QuASAR-MPRA p-values remain well calibrated (or
in the worst case scenario they will tend to be slightly conservative).
We estimate ρ̂l using (0.1) with Mb = M̂b from (0.3) and a standard gradient method
(L-BFGS-B) to maximize the log-likelihood function:
l(ρl; M̂b, ε̂) = log Pr
(
Rl|Nl, ψl = ψ(ρl, ε̂s), M̂b
)
(0.4)
Finally, all parameters are used to calculate the LRT statistic, contrasting H1 : ρl = ρ̂l to
H0 : ρl = rl and the resulting p-value.
For comparison, we performed the original QuASAR analysis on the data as well, as
described in Harvey et al. (2014).
QuASAR meta-analysis
Using the QuASAR approach, we can generate summary statistics of the allelic imbal-
ance that can be used for downstream analyses. For example, to compare DNA to RNA,
or between RNA of different cell-types, or to perform meta-analysis of multiple MPRA li-
braries. Instead of using an estimate of the allelic proportion ρl, in the QuASAR approach
we report the estimate of βl = log(ρl/(1 − ρl)) and its standard error σ̂l using the second
derivative (i.e. Hessian) of the log-likelihood function in (0.4). We prefer the logistic
transformed parameter βl as it provides a more robust fit and the second derivative is
better behaved than that of ρl on the edges.
To illustrate this for the Tewhey et al. (2016) data, we combined the summary statistics
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for the two LCL individuals using standard fixed effects meta-analysis. The effect size βl,n
of each replicate n is weighted by wn,l = 1/σ̂2n,l, to calculate the overall effect size and
standard error:
β∗l =
1
w∗l
∑
n
βn,l wn,l σ
∗
l =
√
1/w∗l (0.5)
where w∗l =
∑
nwn, l. We can then calculate the Z-score and p-value to test for an overall
change between all the RNA replicates combined with respect to the original DNA propor-
tion β0:
Zl =
β∗l − β0
σ∗l
, β0 = log
rl
1− rl
, p = 2Φ(−|Zl|) (0.6)
Across all the paper, p-values were corrected for multiple testing using the Benjamini-
Hochberg′s (BH) method (Benjamini and Hochberg, 1995). To compare the different ap-
proaches we quantified the genomic inflation parameter, λ, for a set of p-values (Yang
et al., 2011). For this we calculated the ratio of the median of the p-value distribution to
the expected median, thus quantifying the extent of the bulk inflation and the excess false
positive rate. We also use a rank sum paired test to assess statistical significance in the
p-value inflation between QuASAR-MPRA and other methods with similar performance.
Simulations
To simulate MPRA data we randomly sampled from a beta-binomial distribution with
parameters set to approximate the real data in Tewhey et al. (2016). The advantage of a
simulation is that we have full knowledge of which SNPs are truly imbalanced and we can
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empirically calculate statistical power (i.e, sensitivity) and FDR under specific assumptions.
The true underlying distribution may not exactly be beta-binomial but simulations are still
very useful to know how the test performs and compares to other tests. We started by
simulating the DNA reads and proportions for each SNP using a beta-binomial. For this we
used the DNA proportion from the Tewhey et al. (2016) data as the expected proportion ρl
and we set the concentration parameter M to be 200, and the total number of DNA reads
N = 10,000.
θl ∼ Beta(ρlM, (1− ρl)M)) RDNAl ∼ Bin(N, θl) (0.7)
After we simulated the DNA counts RDNA, we recalculated the new DNA proportions r∗l =
R∗l /N . The exact value of the parameters used to generate the DNA counts are not very
important and should have no effect for the simulation as the differences are captured on
the RNA data once the DNA proportion is specified.
To simulate the RNA data we need to simulate two conditions: 1) SNPs without ASE
and the same proportion as in DNA, and 2) SNPs with ASE and a different allelic pro-
portion than those in DNA. To do this, we explored different parameter settings for the
concentration parameter M (10, 60 and 100), effect size ∆β (0.5, 1.0 and 2.0) and num-
ber of RNA replicates (2, 5 and 8). The number of reads Nl observed for each SNP was
set up to match the average NA12878 RNA counts for each SNP (so multiple coverages
are being simulated) and we divided these by a constant factor to simulate sequencing
depths (1/2,1/5 and 1/10) lower than those obtained by Tewhey et al. (2016). Each RNA
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replicate was simulated with the same parameter setting.
ρ∗l = logit(logit
−1(r∗l ) + ∆β) (0.8)
θl ∼ Beta(ρ∗lM, (1− ρ∗l )M)) RRNAl ∼ Bin(Nl, θl) (0.9)
To sample from Beta and Bin, we used the rbeta and rbinom in R respectively. The pro-
portion of SNPs with RNA counts with ∆β 6= 0 and simulated to have an allelic imbalance
is 0.1% of the total SNPs. For each simulated data set we then ran the t-test and QuASAR
and adjusted the p-values for multiple testing using the same BH procedure as in the real
data. For each FDR control threshold we empirically calculated power (Sensitivity) and
false discovery rate (eFDR). To ensure that we get robust sensitivity and FDR estimates we
repeated the entire procedure 20 times and reported the average.
Annotation Overlap
Table 9 in Appendix A reports the annotations we have considered with their sources.
More specifically, we considered two major sets of annotations: experimentally and com-
putationally derived. The experimental annotations include allele-specific hypersensitivity
(ASH) from (Moyerbrailean et al., 2016b), dsQTLs (Degner et al., 2012), and GTEx eQTLs
(Consortium et al., 2015).
In terms of computational annotations, a variety of different methods have been used
recently to predict the allelic effect of SNP on TF binding and chromatin accessibility. GKM-
svm (Lee et al., 2015a) uses gapped k-mer frequencies to predict the activity of larger func-
tional genomic sequence elements, including the impact of a variant on DNase I sensitiv-
ity. It utilizes support vector machinery based on the structural risk minimization principle
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from statistical learning theory and kernel function which calculates the similarity between
any two sequences. CATO (Maurano et al., 2015) quantifies the effect of SNPs on the en-
ergy of TF binding, through overlapping SNP DHS profiles with TF motifs and applying a
logistic model which takes into account site dependent features and phylogenetic conser-
vation. DeepSEA (Zhou and Troyanskaya, 2015) uses TF binding, DHS, and histone-mark
profiles with genomic sequence information as input for training a deep learning-based al-
gorithm and predict the effects that sequence alterations have on the chromatin. DeepSEA
has three major features: integrating sequence information from a wide sequence con-
text, learning sequence code at multiple spatial scales with a hierarchical architecture, and
multitask joint learning of diverse chromatin factors sharing predictive features. Finally
we also used CentiSNPs, an annotation that we recently developed (Moyerbrailean et al.,
2016b) that uses the Centipede framework (Pique-Regi et al., 2011) to integrate DNase-
seq footprints with a recalibrated position weight matrix (PWM) model for the sequence
to predict the functional impact of SNPs in footprints. In CentiSNPs, SNPs in footprints
“footprint-SNPs”are further categorized using Centipede hierarchical prior for each allele
as “effect-SNP′′ if the prior relative odds for binding are > 20 or as “Non-effect-SNPs′′
otherwise.
For the other computational annotations we set the following thresholds. To run GKM-
svm (Lee et al., 2015a), we extracted sequences around MPRA variants (19bp total) and
then ran the reference vs alternate allele sequences with either the GM12878 or HepG2
weights. We then used a threshold of < −6 or > 6 for the variant scores. DeepSEA (Zhou
and Troyanskaya, 2015) variant scores were identified using the website tool with a vcf
file input (containing the MPRA variants). The functional significance predictions have a
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threshold of < 0.05. We overlapped SNPs from MPRA counts data with each annotation
type. To identify particular annotations that predict the ASE found in the MPRA, we built
logistic models log(pl/(1−pl)) = β0 +β1×al using the QuASAR p-values (p < 0.001) as the
observed binary outcome, and the genomic annotations al as the predictor. For this type of
analysis we use the nominal p-value (p < 0.001), as we test for an enrichment with respect
to what would be expected from the null uniform distribution (0.1% of the tests). This
nominal p-value corresponds to a FDR threshold of 7.2% for FDR (enrichments are not
sensitive to variations of this threshold). A significant p-value from the annotation logistic
model together with the QQ-plot are useful to evaluate which annotations work best in
predicting changes in gene regulation.
Results
Functional regulatory variants help identify and interpret causal GWAS hits
To better test if the annotated CentiSNPs can help fine-mapping and give a mechanistic
support for variants associated with complex traits, we integrated them into GWAS meta
analyses for 18 traits (see Summary of GWAS meta analysis traits examined.) using the
recently developed hierarchical model fgwas (Pickrell, 2014). Importantly, in this analy-
sis we used as input the association p-values measured or imputed to all known common
variants in the genome. Furthermore, for each trait we compare to a baseline model (Pick-
rell, 2014) that considers previously defined annotations (Maurano et al., 2012; Thurman
et al., 2012) and confounders (e.g., distance to TSS, coding region, and others). For each
trait, we identified factors whose binding sites were enriched for associated SNPs (Figure
3A & B, 18 and Table 6) over the baseline model (the enrichments reported by fgwas are
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log-odds ratios from the model parameters).
Overall, we observed high enrichments for biologically relevant factors. For example,
the enrichment for CentiSNPs in OCT-4 (POU5F1, a TF with a key role in embryonic de-
velopment and stem cell pluripotency (Nichols et al., 1998)) regulatory sequences when
considering genetic variants associated with human height is 6.6-fold higher (95%CI: 3.7-
8.2) than in the baseline model. This is consistent with previous observations of genetic
variants associated with height being enriched in embryonic stem cell DHS sites (Trynka
et al., 2015). We also observed an enrichment for the developmental regulators TBX15
(3.9x), FOXD3 (3.9x), and NKX2-5 (4.7x) for genetic variants associated with height.
From a study of low-density lipoprotein (LDL) levels in the blood, enriched factors include
the liver-specific factor HNF4A (9.1x), as well as several regulators of immune function,
including CREB1 (3.7x), IRF1 (6.2x), and IRF2 (7.1x).
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Figure 3: Integration of annotations into GWAS results. (A & B) Enrichment (log2(change in prior odds w.r.t the baseline model)) of
factors for association with (A) height and (B) low-density lipoprotein levels. Error bars are drawn for 95% confidence intervals. (C &
D) Association plots showing the Bayes factor of each SNP in the displayed region for (C) height and (D) low-density lipoprotein levels.
Shown in red are SNPs with a posterior probability of association >0.4.
Our high resolution annotations allowed us to dissect the most likely functional variant
(posterior probability of association, PPA > 0.2) in 88 previously identified GWAS regions
(Table 7, Figure 20). For all 88 but 2 of these SNPs we have at least a 2-fold increase
on the posterior odds of picking the potentially causal genetic variant according to fgwas
(8.5x median fold increase) when compared to the comprehensive baseline annotation
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used by (Pickrell, 2014). We then performed reporter gene assays for 21 SNPs to validate
the predicted allelic effect on gene expression and the underlying molecular mechanism
(Figure 4 A & B, Table 8, Methods). Among the regions tested we validated that 11 have
enhancer/repressor activity and 10 have variants with allele-specific activity (p < 0.05,
BH-FDR=10%). This corresponds to 48% validation rate which is much greater than the
5% that would be expected by chance (Binomial test p = 2.01 × 10−8). Overall the pre-
dicted effect on binding and the change in gene expression are well correlated (Spearman
ρ=0.612, p-value=0.0032), and the three SNPs with opposite effects may represent bind-
ing sites for repressors. Spearman correlation is robust to outliers, removing potential
outlier rs540909 results in ρ=0.657 (p-value = 0.002).
As an example, rs4519508, associated with a 2.1cm decrease in height (Lango Allen
et al., 2010), is in a binding site for the cell-cycle regulator family E2F (Figure 3D). Our
annotation increased the PPA from a baseline of 10.5% to 44.4%, and it is the highest
associated SNP in the association block (Figure 19A). This E2F footprint is active in >300
tissues (most of them fetal) and we detected ASH at this SNP in lung fibroblasts, validating
that the reference allele at rs4519508 confers stronger binding than the alternate. Inter-
estingly, in the reporter assay we observed 1.5-fold increased expression in the presence
of the alternate allele, suggesting that at this location, E2F is acting as a repressor. Finally,
this SNP is located within the promoter of PPP3R1, a regulatory subunit of calcineurin
important for cardiac and skeletal muscle phenotypes; and a SNP in the same region has
been shown to be associated with endurance (He et al., 2010) in humans. The p-value
of association for this GWAS locus (p = 8.1 × 10−6) does not reach genome-wide signif-
icance in the height meta-analysis data we used (Lango Allen et al., 2010); however, in
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a recent more extensive meta-analysis for height (Wood et al., 2014) this locus achieves
genome-wide significance p = 8.4×10−10, demonstrating that our annotation can be useful
to rescue relevant loci.
Figure 4: Reporter gene assay validation of allelic regulatory activity. (A) Average luciferase expression level for the constructs
containing the reference (blue) and alternate (green) allele, normalized to the empty vector. SNPs with significant allele-specific effect
on gene expression are listed in bold. ∗denotes human orthologs. (B) Change in predicted binding (prior log ratio from the sequence
model, x-axis) versus normalized expression experimentally measured in the reporter assays (y-axis). The black line represents the
best-fit line from a linear model fit on all points.
Finally, a SNP associated with LDL levels, rs532436, is within a footprint for USF, an
E-box motif (Figure 3C). Adding our annotation increased the PPA of the SNP from 39.7%
to 94.7% (Figure 19B). We found that the alternate allele, associated with a 0.0785 mg/dL
increase of LDL in the blood, is predicted to have a lower binding probability and results
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in 1.8-fold lower expression, compared to the reference allele. This SNP is identified by
GTEx (Consortium et al., 2015) as an eQTL for two proximal genes in whole blood: ABO
(p = 5 × 10−5) and SLC2A6 (GLUT6, a class III glucose transport protein; p = 8 × 10−5).
The SNP has an opposite effect on expression of the two genes, with the alternate allele
showing lower expression for ABO and higher expression for SLC2A6.
These results show that our integrated analysis provides support for likely mechanisms
linking regulatory sequence changes to complex organismal phenotypes. Furthermore,
these mechanisms can be directly investigated through molecular studies, providing addi-
tional support that these sequence changes are truly functional.
Applying QuASAR-MPRA to identify ASE
We used the method proposed here, QuASAR-MPRA, to detect ASE in the MPRA data
collected by (Tewhey et al., 2016). In MPRA, ASE is defined as the departure in the RNA
reads from the DNA proportion (the input allelic ratio). Because strand orientation may
affect the enhancer function of the sequences tested, each SNP was tested for ASE in the
two strand orientations separately (forward/reverse). The two LCL biological replicates
were combined using meta-analysis (see Methods). The number of SNPs with significant
ASE (10% FDR) were 309 (forward) and 293 (reverse) in LCLs (Table 10 and Figure 5), 85
(forward) and 84 (reverse) in HepG2 (Table 11 and Figure 21). We then compared these
results to those obtained using other methods previously used for MPRA/ASE analysis
using the same input file with the same pre-processing filters (see Methods).
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Figure 5: Comparing ASE testing methods in LCLs from Tewhey et al. (2016). QQplot depicting the p-value distributions from
testing for ASE using four different methods in LCLs with all SNPs (Left) or SNPs predicted to not have any regulatory effect (non-effect
SNPs, Right). λ measures genomic inflation deviation from the uniform.
While some of the other methods seem to identify a larger number of SNPs with sig-
nificant ASE, the distribution of p-values (Figure 5) shows that those methods have very
skewed distributions. The majority of genetic variants tested are expected to have no im-
pact and only those that were the truly causal eQTL SNP should have a significant p-value.
We do not know a priori which variants have ASE, but in Figure 5 we would expect that
the majority of p-values would follow the expected uniform distribution if the approach
correctly models the data under the null hypothesis. In other words, only a fraction of
MPRA constructs are expected to have significant allelic effects. To better quantify the
departure from the expected distribution of p-values for each testing method we used the
genomic inflation method. In this method, a greater departure from a lambda value of
1 corresponds to greater inflation in the test results (see Appendix A for reverse oligo
results). Based on the genomic inflation value λ, QuASAR-MPRA results in the lowest
inflation, with λ = 1.161. A paired t-test with independent estimation of variance and
Welch′s adjustment, as in (Tewhey et al., 2016), results in a moderately but significantly
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larger λ = 2.89 (p < 2.2 × 10−16). The binomial test produces the greatest inflation, with
λ = 57.95, followed by Fisher′s exact test, as in (Vockley et al., 2015) resulting in λ = 38.68.
The methods with the lowest inflation, QuASAR-MPRA and the t-test, have a 69% match
at 10% FDR.
These results are also similar if we use a different dataset (Ulirsch et al., 2016) (Figure
6). QuASAR-MPRA results in the lowest inflation, with λ = 0.58, while the binomial test
produces the greatest inflation, with λ = 33.31 followed by Fisher′s exact test λ = 16.86.
The paired t-test is relatively well calibrated λ = 1.74 but detects less hits than QuASAR-
MPRA (only 64 constructs containing 53 variants at FDR 10%). Using QuASAR-MPRA we
were able to identify 103 constructs containing 95 variants (FDR 10%) with significant
ASE.
Figure 6: Comparing ASE testing methods in Ulirsch et al. (2016). QQplot depicting the p-value distributions from testing for ASE
using four different methods in K562 for all SNPs. λ measures genomic inflation deviation from the uniform.
Alternatively, we also considered the p-value distributions only for the SNPs not pre-
dicted to affect TF binding (non-effect SNPs), as these SNPs are more likely to be true
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negatives 5. Note that our computationally predicted effects are not a perfect gold stan-
dard and in fact one major application of this type of data and its analysis is to precisely
validate the accuracy of these computational annotations and predictions as we will show
later. Nevertheless, we see (in Figure 5, 6 and 21) that the two methods with lowest
lambda values show an even lower departure from the null, consistent with the computa-
tional method correctly predicting a large number of true positives.
Applying QuASAR-MPRA to simulated data
To further investigate our proposed new method we used simulated data where we
know exactly the underlying true ASE signal to evaluate the detection accuracy. It is im-
portant to note that the simulation conditions may not exactly match those from the real
data (see Methods) but they are very useful for getting more insights about the scenarios
that may have larger impact on performance. Here we only compare the two methods that
seem to be well-calibrated under the null hypothesis QuASAR-MPRA and the t-test. Under
the null distribution for all our simulations both tests do not show a significant departure
from the expected uniform distribution for the p-values.
We then compared results from QuASAR-MPRA and the t-test in scenarios when a
fraction of the tests do have ASE (see Methods). In every condition QuASAR-MPRA has
greater sensitivity to detect ASE than the t-test (Figure 7). The t-test seems to perform
better when the over-dispersion is low (M=100), or when the effect size of ASE is high
(∆β=2). QuASAR-MPRA also handles well low coverage data and a small number of
replicates to achieve good statistical power (Figure 7). This is consistent with our original
findings with QuASAR (Harvey et al., 2014) demonstrating that we can measure ASE in a
small number of replicates if there is enough read coverage. The t-test appears to require a
35
large number of replicates in order to have power to detect ASE as compared to QuASAR-
MPRA.
Figure 7: Exploring the performance across multiple simulated conditions. Plots depicting empirical power (sensitivity, Left y-
axis) and empirical FDR (eFDR, Right y-axis) achieved at different BH-FDR control levels (x-axis) for ASE testing using QuASAR-MPRA
(green) and a t-test (blue) across multiple simulated conditions (rows). Default conditions are M=60, ∆β=1, 5 replicates, and reads/5.
Each row explores changing different simulation settings: A) over-dispersion high (M=10), medium (M=60) and low (M=100); B)
effect-size high (∆β=2), medium (∆β=1) and low (∆β=0.5); C) number of replicates (3, 5, or 8) D) overall sequencing depth
compared to (Tewhey et al., 2016) (1/10, 1/5, or 1/2).
Validation of experimental and computational annotations for functional non-coding
variants
High-throughput reporter assays can be used not only to fine-map causal variants in
both GWAS and eQTL studies, but also to validate SNP functional annotations (Kwas-
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nieski et al., 2014). Here we take advantage that the p-values derived from QuASAR
are well calibrated under the null hypothesis to examine enrichments for low p-values in
both experimentally and computationally derived annotations for allele-specific effects on
TF binding. The experimentally derived annotations included LCL dsQTLs (Degner et al.,
2012), allele-specific hypersensitivity (ASH) SNPs (Moyerbrailean et al., 2016b), and GTEx
eQTLs (Consortium et al., 2015). In both LCLs (Figure 8) and HepG2 (Figure 22), ASH
SNPs had the greatest departure from the null, followed by LCL dsQTLs.
Figure 8: Validating experimental annotations in LCLs. QQ plot depicting the p-value distributions from testing for ASE using
QuASAR, overlapping with experimental genomic annotations including allele-specific hypersensitivity (ASH) (Moyerbrailean et al.,
2016b), DNase I sensitivity QTLs (dsQTLs) (Degner et al., 2012) and GTEx (Genotype-Tissue Expression) lead SNP in LCLs (Consortium
et al., 2015). An annotation enrichment p-value is reported next to their labels, but only for those annotations that are significantly
enriched for small QuASAR-MPRA p-values according to the logistic model (see Methods).
We then asked which computational annotations seem to be the most complete and
accurate predictors of the effect of a sequence variant on gene regulation as validated by
MPRA. We considered effect-SNPs active in LCLs or HepG2 (Moyerbrailean et al., 2016b),
non-effect SNPs (negative control) (Moyerbrailean et al., 2016b), predicted functional
SNPs from CATO (Maurano et al., 2015), GKM-svm (Lee et al., 2015a) (a gapped kmer
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sequence-based computational method to predict the effect of regulatory variation), and
DeepSEA (Zhou and Troyanskaya, 2015) (predicts genomic variant effects at the variant
position using deep learning-based approach). Each of the functional annotations show
marked differences in p-value distribution. As expected, SNPs in active TF footprints, but
not predicted to affect binding, show no departure from the overall distribution. In both
LCLs (Figure 9) and HepG2 (Figure 23), CATO and GKM-svm SNPs had the greatest de-
parture from the null, closely followed by effect-SNPs.
However, effect-SNPs annotated a considerably larger number of SNPs for both cell-
types and were also able to predict cell type-specific effects. LCL effect-SNPs in LCLs had
a p-value distribution with a greater departure from the null than the HepG2 effect-SNPs
(Figure 24) (p = 1.77 × 10−15 for LCL effect-SNPs vs p=0.14 for HepG2 effect-SNPs),
whereas HepG2 effect-SNPs in HepG2 had a p-value distribution with a greater departure
from the null than the LCL effect-SNPs (p = 1.81 × 10−4 for HepG2 effect-SNPs vs p =
1.06× 10−7 for LCL effect-SNPs Figure 25). The differences found here in HepG2 however
are minor, potentially due to fewer annotations (993 annotated LCL effect-SNPs vs 193
HepG2 effect-SNPs).
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Figure 9: Validating computational genomic annotations in LCLs. QQ plot depicting the p-value distributions from testing for
ASE using QuASAR, overlapping with computational genomic annotations in LCLs. Effect-SNP scores have a threshold of < −3 or
> 3. CATO (Maurano et al., 2015) prediction scores have a threshold of > 0.1. GKM-svm (Lee et al., 2015a) gapped kmer sequence-
based computational method to predict the effect of regulatory variation has a threshold of < −6 or > 6. DeepSEA (Zhou and
Troyanskaya, 2015) predicts genomic variant effects at the variant position using deep learning-based algorithmic framework. The
functional significance predictions have a threshold of < 0.05. An annotation enrichment p-value is reported next to their labels,
but only for those annotations that are significantly enriched for small QuASAR-MPRA p-values according to the logistic model (see
Methods).
Finally, to formally quantify which annotations are the best predictors of the ASE found
in the MPRA, we used all experimental and computational annotations within a logistic
model to predict which SNPs in the MPRA data have a nominally significant QuASAR p-
value (p < 0.001). The top predictors were GKM-svm SNPs (p < 2×10−16) and effect-SNPs
(p = 2.17 × 10−15) in LCLs (Table 12). In HepG2, effect-SNPs were the greatest predictor
(p = 1.18× 10−10) (Table 13).
Discussion
High throughput reporter assays have proven extremely useful for the experimental
validation of enhancer regions. The recent adaptation of MPRA to investigate ASE addi-
tionally allows for validation of regulatory variants in TF binding sites, which have been
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shown to be functionally relevant to fine map eQTLs and GWAS signals. These large
datasets, however, require analysis methods to handle the intrinsic overdispersion resulting
from the original plasmid proportions, variability in the allelic imbalance, and base-calling
errors.
The major advantage of QuASAR-MPRA compared to other well calibrated methods is
that it requires a small number of replicates allowing for a more efficient study design.
QuASAR-MPRA (along with the other methods used here) resulted in a computation time
of under a minute and should scale linearly with the number of SNPs being tested. Our
QuASAR-MPRA approach identifies causal regulatory variants from high-throughput re-
porter assays by taking into account overdispersion present in the data. This results in a
well calibrated test, with minimal inflation, as determined by lambda values close to 1. In
addition to being a robust method to identify ASE in high throughput reporter assays, this
method estimates effect sizes and standard errors for each SNP, which can be used in fixed
effects meta-analysis to easily combine datasets. Additionally, we retain a larger number
of discoveries 602 (FDR 10%) compared to the original MPRA study (441 at 10%FDR) in
LCLs.
Finally, we show that the allele-specific regulatory functions identified with QuASAR-
MPRA can be used to validate genomic annotations as predictors for allele-specific effects.
Knowing which annotations are the best predictors can aid in identifying true causal SNPs.
Here we find that LCL dsQTLs and effect-SNPs are significantly predictive of ASE in LCLs
and HepG2 with CATO, while GKM-svm is significant in only LCLs. Using genomic annota-
tions can additionally help us assign mechanism of action to these regulatory variants. If
a variant impacts a TF binding site for example, this can lead to gene expression changes,
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and therefore phenotypic effects. The less compelling results found in HepG2 may be due
to HepG2 having fewer RNA replicates in the MPRA dataset than LCLs. Also there is less
data available by ENCODE for the various genomic annotations, likely due to the fact that
LCLs (particularly GM12878) are a tier 1 cell line and that other studies also used it for
dsQTL analysis (Degner et al., 2012), where HepG2 is only a tier 2 cell type.
Here we have used QuASAR-MPRA on two MPRA datasets, however this method can
potentially be used for other high-throughput reporter assays, such as the ones derived
from the STARR-seq protocol (e.g., POP-STARR-seq) (Vockley et al., 2015) and CRE-seq
protocols (Kwasnieski et al., 2012), and in the context of high-throughput mutagenesis ex-
periments. As the quest for functional validation of regulatory variants becomes more and
more wide-spread, these high throughput reporter assays, when combined with a robust
statistical test, represent a unique resource to functionally characterize genetic variants at
an unprecedented and expandable scale.
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CHAPTER 3 High throughput characterization of genetic effects on
DNA:protein binding and gene transcription 2
Introduction
Genome wide association studies (GWAS) have identified thousands of common ge-
netic variants associated with complex traits, including normal traits and common dis-
eases. Many GWAS hits are in non-coding regions, so the underlying mechanism leading
to specific phenotypes is likely through disruption of gene regulatory sequence. Quantita-
tive trait loci (QTLs) for molecular and cellular phenotypes (Dermitzakis, 2012), such as
gene expression (eQTL) (Brem and Kruglyak, 2005; Stranger, 2007; Innocenti et al., 2011;
Wen et al., 2015; Aguet et al., 2017), transcription factor binding (Kasowski et al., 2010),
and DNase I sensitivity (dsQTL) (Degner et al., 2012) have been crucial in providing strong
evidence and a better understanding of how genetic variants in regulatory sequences can
affect gene expression levels (Albert and Kruglyak, 2015; Aguet et al., 2017; Gibbs et al.,
2010; Melzer et al., 2008). In recent work, we were able to validate 48% of computation-
ally predicted allelic effects on transcription factor binding through traditional reporter
assays (Moyerbrailean et al., 2016b). However, traditional reporter assays are limited by
the time and the cost of testing variants one at a time.
Massively parallel reporter assays (MPRA) have been developed for the simultaneous
measurement of the regulatory function of thousands of constructs at once. For MPRA, a
pool of synthesized DNA oligos containing a barcode at the 3’UTR of a reporter plasmid is
transfected into cells, and transcripts are isolated for RNA-seq. Expression driven by the
2This chapter originally appeared as: Kalita, C. A., Brown, C. D., Freiman, A., Isherwood, J., Wen, X.,
Pique-Regi, R., & Luca, F. (2018). High throughput characterization of genetic effects on DNA:protein
binding and gene transcription. Genome Research, gr.237354.118.
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synthesized enhancer region is estimated from the number of RNA reads normalized by
the number of corresponding DNA reads (Melnikov et al., 2012; Kwasnieski et al., 2012;
Patwardhan et al., 2012; Sharon et al., 2012; Kwasnieski et al., 2014). An alternative to
MPRA is STARR-seq (self-transcribing active regulatory region sequencing) (Arnold et al.,
2013), whose methods involve fragmenting the genome and cloning the fragments 3′ of
the reporter gene. The approach is based on the concept that enhancers can function in-
dependently of their relative positions, so putative enhancers are placed downstream of
a minimal promoter. Active enhancers transcribe themselves, with their strength quanti-
fied as the amount of RNA transcripts within the cell. Because they do not use separate
barcodes, STARR-seq approaches have streamlined protocols that allow for higher through-
put. Recently, high-throughput assays have been used to assess the enhancer function of
genomic regions (Arnold et al., 2013; Wang et al., 2017), the allelic effects on gene ex-
pression for naturally occurring variation in 104 regulatory regions (Vockley et al., 2015),
fine-map variants associated with gene expression in lymphoblastoid cell lines (LCLs) and
HepG2 (Tewhey et al., 2016), and fine-map variants associated with red blood cell traits in
GWAS (Ulirsch et al., 2016). These and other approaches with higher scalability and effi-
ciency are necessary to validate and understand the validity of computational predictions
and statistical associations for likely causal genetic variants.
In addition to using reporter assays to measure enhancer function on gene expression,
there are several methods to directly measure binding affinity of DNA sequences for spe-
cific transcription factors. These methods include Spec-seq (Stormo et al., 2015), EMSA-
seq (electrophoretic mobility shift assay-sequencing) (Wong et al., 2011), and BUNDLE-
seq (Binding to Designed Library, Extracting, and sequencing) (Levo et al., 2015). In
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these assays, synthesized regions are combined in-vitro with a purified transcription factor.
The bound DNA-factor complexes are then isolated by polyacrylamide gel electrophoresis
(PAGE), where sequencing of the derived libraries allows for quantification of the binding
strength of regulatory regions. The benefit to these methods is that it is possible to assay
any potential genetic variant of interest. In-vivo methods (such as DNase-seq, ChIP-seq),
instead, are limited to existing variation within a given sample. Also, in-vivo methods
cannot look at each transcription factor separately to identify the specific factor directly
causing the change in binding, as the binding could be indirect with any number of co-
factors. While BUNDLE-seq compared binding and reporter gene expression, and EMSA
has been previously used to ascertain allelic effects, none of the high-throughput EMSA
methods have been previously used to determine allelic effects on binding.
Methods
BiT-STARR-seq
Tables 15, 16, 17 report the annotations we have considered with their sources and
Tables 29, 25 include the library composition. Each regulatory region was designed to have
two oligos: one for each of the alleles. DNA inserts 230bp long, corresponding to 200bp of
regulatory sequence, were synthesized by Agilent to contain the regulatory region and the
SNP of interest within the first 150bp (Figure 27). We performed a first round of PCR to
double strand the oligos and complete the sequencing primers, followed by a subsequent
round of PCR to amplify the material. Plasmid pGL4.23 (Promega) was linearized using
CloneAmp HiFi PCR Premix (Clontech), primers [STARR_F_SH and STARR_R_SH]. Inserts
were cloned into the linear plasmid using standard Infusion (Clontech) cloning protocol.
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Clones were transformed into XL10-Gold Ultracompetent Cells (Agilent) in a total of 7
reactions. DNA was extracted using Endofree maxiprep kit (Qiagen).
The DNA library was transfected into LCLs (GM18507) using standard nucleofection
protocol, program DS150. We performed nine biological replicates of the transfection from
7 independent cell growth cultures. After transfection, cells were incubated at 37◦C and
5% CO2 in RPMI1640 with 15%FBS and 1% Gentamycin for 24h. Cell pellets were then
lysed using RLT lysis buffer (Qiagen), and cryopreserved at -80◦C. RNA libraries. Total
RNA was isolated from the thawed lysates using RNeasy Plus Mini Kit (Qiagen). RNA-seq
libraries from the poly-Adenylated RNA were prepared using a custom protocol described
in Appendix B: Library preparation. We prepared 7 replicates of the DNA library using a
modified version of the PCR protocol as described in (Buenrostro et al., 2013) (Appendix
B: Library preparation).
BiT-BUNDLE-seq
We developed BiT-BUNDLE-seq, by modifying the design of the BUNDLE-seq protocol
(Levo et al., 2015). Specifically, input DNA sequences were extracted from the BiT-STARR-
seq DNA plasmid library. We used N-terminal GST-tagged, recombinant human NFKB1
from EMD Millipore. Experiments were performed in triplicates for each NFKB1 concen-
tration. Libraries extracted from the bound and unbound DNA bands after PAGE were
quantified and loaded on the Illumina NextSeq 500 for sequencing.
Data Processing
Reads were mapped using the HISAT2 aligner (Kim et al., 2015), using the 1Kgenomes
snp index so as to avoid reference bias. Realigning the reads to GRCh38 should not affect
the conclusions as any problematic region of the genome is excluded from any analysis
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(Appendix B: Oligo selection and design). We then ran UMItools (Smith et al., 2017)
using standard flags to remove duplicates. To identify SNPs with allele-specific effects, we
applied QuASAR-MPRA (?), where for each SNP the reference and alternate allele counts
were compared to the DNA proportion. QuASAR-MPRA results from each replicate were
then combined using the fixed effects method, and corrected for multiple tests (Benjamini
and Hochberg, 1995).
Each replicate for the bound and unbound libraries from BiT-BUNDLE-seq were run
through QuASAR-MPRA using the calculated reference proportion (combined unbound
and bound DNA). These were then compared using ∆AST (Moyerbrailean et al., 2016a)
to identify ASB in the bound fraction that is differential relative to the unbound fraction.
The replicates were combined using Stouffer′s method (STOUFFER et al., 1949) to identify
ASB for each NFKB1 concentration, and combined again to identify the total ASB. Libraries
were additionally analyzed with DESeq2 (Love et al., 2014) to discriminate between bound
and unbound constructs.
Results
We have developed a new streamlined method called BiT-STARR-seq (Biallelic Targeted
STARR-seq) to test for allele specific effects in regulatory regions (Figure 10A, 27). We
selected different categories of regulatory variants for this study including eQTLs (Wen
et al., 2015; Innocenti et al., 2011), CentiSNPs (Moyerbrailean et al., 2016b), ASB SNPs
(Moyerbrailean et al., 2016b), variants associated with complex traits in GWAS (Pick-
rell, 2014), and negative ASB controls (Moyerbrailean et al., 2016b) for a total of 50,609
SNPs (see Methods). We designed two oligos targeting each of the alleles for a SNP and
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containing the regulatory region (200bp) centered on the SNP (Figure 10A, 27, see Meth-
ods). We also included the use of unique molecular identifiers (UMIs), added during
cDNA synthesis. With these random UMIs we are in effect tagging identifiable replicates of
the self-transcribing construct, which improves the analysis of the data by accounting for
PCR duplicates. Our protocol also has the advantage of being highly streamlined. Unlike
STARR-seq, our method does not require preparation of DNA regions for use in the assay,
such as whole genome fragmentation (Arnold et al., 2013), or targeting regions (Vanhille
et al., 2015), while, similar to STARR-seq, it requires only a single cloning and transfor-
mation step. Because the UMIs are inserted after transfection, there are no additional
bottleneck issues (due to library complexity) in the cloning and transformation steps.
We generated 7 replicates of the DNA library, which were highly and significantly cor-
related (Figure 28, Spearman′s ρ = (0.97, 0.98), p-value<0.01). The DNA library was then
transfected in LCLs (9 biological replicates) and we were able to recover a total of 43,500
testable SNPs (see methods for RNA counts filter). Read counts for the 9 biological repli-
cates were highly correlated (Figure 29, Spearman′s ρ = (0.35, 0.72), p-value<0.01). To
identify SNPs with allele-specific effects, we applied QuASAR-MPRA (?). For each SNP, the
reference and alternate allele counts were compared to the DNA proportion in the plasmid
library. We identified a total of 2,720 SNPs with ASE from the combined replicates (FDR
10%) (Table 14). To investigate the importance of UMIs in this experimental approach, we
re-analyzed our data without removing duplicates. For the combined replicates, inflation
(genomic inflation test, see Methods) is greatly increased (from 1.10 to 1.73). If only a
single RNA library replicate is considered the number of detected ASE is about 4x reduced
(Figure 10B).
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SNPs with ASE are significantly enriched for variants predicted to impact transcription
factor binding (CentiSNPs) (Moyerbrailean et al., 2016b) (Figure 10C, 30, Table 15, Table
18, Fisher′s exact test OR=2.49, p-value=4.55 × 10−06). Additionally, SNPs with ASE are
enriched for low p-values in an eQTL mapping study performed in immune cells (Nédélec
et al., 2016) (Figure 10D, Table 17), thus confirming that our synthetic oligos can repro-
duce allele-specific regulatory effects observed in a native (non-episomal) cellular context.
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Figure 10: BiT-STARR-seq and BiT-BUNDLE-seq identify regulatory variants in non-coding regions. A) Experimental outline.
Oligos targeting the regulatory regions of interest (and either reference or alternate alleles) are designed to contain, on their ends,
15bp matching the sequencing primers used for Illumina NGS. The DNA library is used both in the BiT-STARR-seq and BiT-BUNDLE-seq
experiments. UMIs are added during cDNA synthesis for the BiT-STARR-seq RNA-seq library and prior to PAGE in the BiT-BUNDLE-seq
protocol. B) QQplot depicting the p-value distributions from QuASAR-MPRA for a single experimental replicate processed without
removing duplicates (purple) or after removing duplicates using the UMIs (pink). C) QQplot depicting the p-value distributions from
the ASE test performed using QuASAR-MPRA on all replicates after removing duplicates. CentiSNPs are in (green)(Moyerbrailean et al.,
2016b) while SNPs in the negative control group are in (grey). D) QQplot depicting the p-value distributions for eQTLs from (Nédélec
et al., 2016). SNPs with significant ASE (FDR 10%) are in (blue) or not significant ASE are in (grey).
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Motif, regulatory region size and chromatin context effects
The CentiSNP annotation is informative of the specific transcription factor motif being
disrupted by a SNP. By leveraging this information, we were able to analyze allelic effects
for specific transcription factor motifs (Figure 11A, Table 19). Additionally, by combining
the ASE results with the direction of the motif, we can characterize whether the motif
is active in both directions or only in one direction. This would suggest that some TF
binding motifs tend to function specifically in one direction. We found that when both
alleles are covered in both directions, the allelic effects on gene expression tend to agree
in direction and magnitude. If we categorize these directional allelic effects per motif,
we do not observe major differences with the notable exception of CTCF (Figure 11B).
Specifically, we find that SNPs in footprints for CTCF are significantly enriched (Fisher′s
exact test OR=1.57, Bonferroni p=0.02) for ASE when the direction of transcription of
the reporter gene is opposite to that of the motif strand (Figure 11C).
While oligos were designed to have the variant centered in the middle of the synthe-
sized region, this does not necessarily mean that the SNP is centered in a DNase window
(Figure 27). While position within the window does not affect the ASE signal, the main
effect seems to depend on the presence / absence of the tested site within the DNase win-
dow (Figure 31) and in a lesser degree it depends of the peak size (Figure 32). SNPs were
originally selected based on the CentiSNP annotation, but when we considered chromatin
states (Broad ChromHMM state) we detect enrichment for promoter state among SNPs
with ASE (Figure 11D).
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Figure 11: ASE for individual transcription factors. A) QQplot depicting the ASE p-value distributions from QuASAR-MPRA, for SNPs
overlapping with E2F footprint annotations. SNPs predicted to alter binding (CentiSNPs) are represented in green, while SNPs that
are in E2F but predicted to have no effect on binding are in grey. B) Enrichment for ASE in individual transcription factor binding
sites calculated when motif strand matched the BiT-STARR-seq oligo transcription direction. Odds ratio (y axis) for each transcription
factor tested (x axis) is shown in the barplot, error bars are the 95% CI from the Fisher′s exact test. Odds ratios below the dotted line
represent enrichment for opposite direction oligo/motif configuration. Stars are shown above significant results (Bonferroni adjusted
p-value <0.05). C) QQplot depicting the ASE p-value distributions from QuASAR-MPRA, overlapping with CTCF footprint annotations.
In red are the SNPs where the motif strand matches the BiT-STARR-seq oligo direction relative to the TSS, in blue where the motif strand
is the opposite of the BiT-STARR-seq direction. D) QQplot depicting the ASE p-value distributions from QuASAR-MPRA, overlapping
with chromatin state annotations.
Allele specific binding for NFKB1
In order to understand the effect of a regulatory variant on complex traits it is neces-
sary to first dissect the molecular function that is impacted by the nucleotide change. The
CentiSNP prediction provides specific hypotheses for allelic effects on transcription factor
binding that can be directly tested experimentally. Further matching ASB to ASE identified
in BiT-STARR-seq would provide a complete molecular mechanism, from predicted binding
51
effects, to experimentally validated binding effects, to validated effects on expression. Due
to the enrichment of CentiSNPs among SNPs with ASE in BiT-STARR-seq, we performed
BiT-BUNDLE-seq to validate their effect on transcription factor binding. This is a new and
efficient extension of high throughput reporter assays, since it uses the same input DNA
library. We performed BiT-BUNDLE-seq with purified NFKB1 (at three different concentra-
tions), which is an important regulator of the immune response in LCLs and other immune
cells (Li and Verma, 2002; Beinke and Ley, 2004; Smale, 2010). Previous studies have
successfully identified ASB from ChIP-seq for all NF-kB subunits in LCLs (Zhao et al., 2014;
Heinz et al., 2010; Jin et al., 2013; Kasowski et al., 2010; Lim et al., 2007; Martone et al.,
2003) and NFKB1 footprints are induced in response to infection (Pacis et al., 2015). Ad-
ditionally, NF-kB complex was found to be 50 fold enriched for reQTLs from response to
Listeria and Salmonella (Nédélec et al., 2016).
We first analyzed NFKB1 binding between the bound and unbound libraries and iden-
tified 9,361 significantly (logFC>1 and FDR<1%) over-represented regions in the bound
library (Table 20, 21, 22, 23). As expected, these regions were enriched (OR=11.70 to
13.75, p-value=7.95×10−27 to 1.23×10−15) for NF-kB complex footprints (Figure 12A, 33),
with a higher portion of these regions in the mid concentration of NFKB1 as compared to
the low or high concentrations (Figure 12B). We hypothesize that this is because the low
concentration doesn′t capture all of the NFKB1 binding, whereas the high concentration
likely results in non-specific binding. We then used ∆AST (Moyerbrailean et al., 2016a)
to identify ASB in the bound library (as compared to the unbound library), and combined
the replicates using Stouffer′s method (see Methods, Figure 12C).
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Figure 12: Allele-specific binding for NFKB1. A) Density plot of the logFC (from DESeq2) between bound and unbound DNA fractions
from the BiT-BUNDLE-seq experiment. In red are the regions containing a SNP in a NF-kB complex footprint, in blue the regions
containing a SNP in footprints for other transcription factors. B) Barplot representing the number of independent enhancer regions in
bound (dark color, DESeq2 logFC>1 and FDR<1%) and unbound (light color) DNA. NFKB1 concentration and presence of a NF-kB
complex footprint are indicated in the two columns on the left of the panel. C) QQplot depicting the p-value distributions from testing
for ASB signal specific to the bound DNA fraction using ∆AST (black) and SNPs in the negative control group are in (grey). D) QQplot
depicting the ASE p-value distribution from QuASAR-MPRA for SNPs with significant (FDR<10%) ASB (green), SNPs with significant
(FDR<10%) ASB and are also in CREB1 or AML1 footprints (maroon), or not significant ASB (grey) in the BiT-BUNDLE-seq experiment.
We successfully identified 386 SNPs at low concentration, 797 SNPs at mid concentra-
tion, and 894 SNPs at high concentration with significant ASB at 10% FDR (Figure 12D,
34), for a total of 2,684 SNPs when aggregating all experiments (Table 16, 24). These
spanned our designed regulatory categories, with the greatest number covering CentiS-
NPs (Table 25). When we considered these ASB SNPs in combination with the ASE results
from the BiT-STARR-seq (Figure 35), we found that SNPs with ASE are enriched for NFKB1
ASB (Figure 12D, Fisher′s exact test (OR=2.04, p-value=1.51 × 10−16)). For ASB variants
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not showing ASE, we found that there is enrichment for these being in either the CREB1
or AML1 motifs (Figure 12D, 36, Fisher′s test see Table 26), which are factors known to
antagonize NF-kB complex binding (Ollivier et al., 1996; Parry and Mackman, 1997; Nak-
agawa et al., 2009, 2011). This confirms our hypothesis that disruption of NFKB1 binding
is one of the mechanisms underlying allele-specific expression in our dataset.
Overlap with signals from GWAS
We used ASB and ASE in combination with transcription factor binding motifs to assign
mechanistic function to putatively causal SNPs linked to complex traits. We found 2,054
CentiSNPs with ASB (p-value<0.05) and 1,769 CentiSNPs with ASE (p-value<0.05) asso-
ciated to a complex trait in the GWAS catalog (Table 27, 28) or from fgwas (Moyerbrailean
et al., 2016b). Considering all SNPs tested, there are 173 SNPs that have both ASB and
ASE (FDR 10%), and 164 of them (95%) are also associated with a complex trait . We
were able to dissect the molecular mechanism for rs3810936, a variant associated with
risk for Crohn′s disease in multiple populations (Yamazaki et al., 2005; Franke et al., 2010;
Lee et al., 2015b; Baskaran et al., 2014) (Figure 13A,B). This variant is a CentiSNP for the
factor Hmx3 (Nkx5-1) and we find ASB for NFKB1 (p-value=0.006) in the BiT-BUNDLE-
seq assay and ASE (p-value=0.034) in both directions in the BiT-STARR-seq. This SNP is a
synonymous variant in gene TNFSF15 (also known as TL1A), which encodes for a cytokine
that belongs to the tumor necrosis factor (TNF) ligand family.
54
Figure 13: Overlap with GWAS. A) Integration of prediction, BiT-BUNDLE-seq, BiT-STARR-seq and GWAS results for Crohn′s disease risk
variant rs3810936. Triangles represent transcription factors. B) Comparing allelic effects from computational prediction to phenotype
for rs3810936. Predicted log odds score is the reference prior log odds - alternate log odds from the CentiSNP annotation. BiT-BUNDLE-
seq Z-score is the Z-score from the meta-analysis of ASB from all 3 concentrations of NFKB1. BiT-STARR-seq Z-score is the Z-score
from meta-analysis of ASE for nine experimental replicates. GWAS OR is the odds ratio from rs3810936 alternate allele with Crohn′s
disease (Yamazaki et al., 2005; Franke et al., 2010; Lee et al., 2015b; Baskaran et al., 2014). All scores are signed relative to the risk
allele, which is the alternate allele.
Increased TL1A expression has been reported in inflamed Crohn′s disease tissue com-
pared with non-inflamed areas, and in ulcerative colitis patient serum (Bamias et al., 2010,
2003; Prehn et al., 2004). TL1A gives costimulatory signals to activated lymphocytes
through binding to death-domain receptor 3 (DR3) (Migone et al., 2002) which induces
the secretion of interferon gamma (IFNG) (Papadakis et al., 2005; Prehn et al., 2004). This
gene modulates Th-1 and Th-17 (Bamias et al., 2003; Takedatsu et al., 2008), creating an
immunological state that leads to the mucosal inflammation of Crohn′s disease. Stimu-
lation of the TL1A pathway, in monocytes and T cells from patients carrying the disease-
associated TL1A SNPs, showed higher levels of TL1A expression, therefore aberrant TL1A
expression may be a factor driving IBD development (Michelsen et al., 2009; Kakuta et al.,
2009). This gene additionally has been found to be downregulated in response to dexam-
ethasone (Moyerbrailean et al., 2016a), a corticosteroid used to treat many inflammatory
and autoimmune conditions. While this variant is not found in ChIP-seq from ENCODE,
ENCODE studies used RELA (p65) for NF-kB subunit, where our study used NFKB1 (p50).
We therefore identify a novel variant that disrupts binding of NFKB1, where the alternate
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allele (C) has increased binding. This leads to an increase in gene expression for the alter-
nate allele, which is also the risk allele for Crohn′s disease (OR=1.21, p-value=1× 10−15).
Discussion
The recent adaptation of MPRA to investigate ASE allows for validation of regulatory
variants in transcription factor binding sites, which have been shown to be functionally
relevant to fine map eQTLs (Tewhey et al., 2016) and GWAS signals (Ulirsch et al., 2016).
However, the use of functional genomics to select relevant regions prior to experimental
validation can reduce the number of sites it is necessary to validate. We developed a high
throughput reporter assay that synthesizes these selected regions (similar to MPRA), clones
them in 3′ of the reporter gene (similar to STARR-seq), and includes the addition of a UMI
during cDNA synthesis (new to our protocol). This is the most streamlined protocol to
date, and allows for removal of PCR duplicates which reduces noise in the data for greater
power to detect ASE.
Our results show that using existing annotations to prioritize regulatory variants for
high-throughput reporter assays is an effective strategy. The CentiSNP annotation in par-
ticular contains information that can be used to analyze ASB/ASE for individual transcrip-
tion factor motifs and investigate potential molecular mechanisms of action. We found
that direction is an important factor in the case of CTCF, most likely due to how CTCF
functions as an insulator between the enhancer and the promoter when they are in anti-
parallel directions. Previous studies have shown that CTCF, a well characterized insulator,
has binding sites at the anchors of chromatin loops. These are arranged in forward-reverse
orientations (Guo et al., 2015; Alt et al., 2013; Guo et al., 2012; Monahan et al., 2012;
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Rao et al., 2014; Vietri et al., 2015), where the relative positions and orientations of the
binding sites are important for the mechanism of action (Guo et al., 2015). In our case,
the interaction could be mediated either by the basal transcriptional machinery at the TSS
or also an additional weak CTCF binding site (M01259) that is present in the promoter
and could help to establish a DNA loop. However, there may be alternative explanations
for this result as reporter assays may not reflect the native regulatory landscape in human
cells (Muerdter et al., 2017; Huerfano et al., 2013).
Generally, caution should be used in interpreting reporter assay gene expression dif-
ferences across cell types, because transfection may perturb the cell state. However, it
is important to highlight that any trans-acting effects (e.g., promoter strength, type 1 in-
terferon response activation) should affect both alleles similarly and therefore should not
induce false positives in the allele-specific signal.
We used our library of oligos also in a BiT-BUNDLE-seq assay for identification of ASB
for NFKB1. This is a novel approach to combine ASB and ASE identification in high
throughput assays using the same sequences. Our results show that this integration is
a useful approach to validate the molecular mechanism for specific transcription factors.
Allelic effects on transcription factor binding and gene expression are not always concor-
dant. Some of this discordance is due to lack of power to detect ASB/ASE overlap, as
well as other technical considerations. For example, in BiT-BUNDLE-seq only one single TF
(NFKB1) is available for binding, whereas in BiT-STARR-seq, other co-factors are present
in the cell to affect binding. Additionally, there can be discordance in direction of effect,
where, for example, an allele can lead to increased binding of a factor with repressing ac-
tivity on gene expression (e.g. variants in CREB1/AML1 binding sites). These regulatory
57
events are likely to be captured in the BiT-STARR-seq assay, which is performed in LCLs
where CREB1, AML1 and NFKB1 are active. These results highlight that multiple type
of assays are necessary to capture the detailed molecular mechanism of gene regulation.
Additionally, integration with GWAS can identify and further characterize the molecular
mechanisms linking causal genetic variants with complex traits.
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CHAPTER 4 Rapid profiling of regulatory regions and variants to
study GxE in complex traits3
Introduction
A large fraction of loci important in determining human traits and disease conditions
are located in non-coding regions of the genome. These regions likely contain specific
regulatory sequences that control gene transcription and can also interact with changes
in the cellular environment (e.g. drug treatment). Recent large scale efforts in functional
genomics have facilitated the profiling of regulatory sequences across many cell-types and
tissues (Consortium, 2012; Consortium et al., 2015), yet we are still very far from mapping
the sequences that control the transcriptional response to many external stimuli.
Importantly, much of the missing heritability in GWAS may be a consequence of small
effect sizes dampened by unaccounted environmental interactions. It can be difficult to
study the effect of the environment on complex traits however, as the (human) environ-
ment is very complicated. For example, in GWAS studies it would be very hard to test for
some environmental influences while controlling for all others. One viable alternative to
identify GxE is to use the cellular environment as a proxy. Using an in-vitro system with
relevant cell-types, we can better control for environment and measure molecular pheno-
types. Many studies have used this system to study the differences in gene expression due
to treatments. One common major cellular pathway studied is the glucocorticoid response
(Mukherjee et al., 2017; Chang et al., 2015; Poon et al., 2012; Richards et al., 2017). It’s
beneficial role in human health dates all the way back to 1950 where it was used to treat
3Parts of this chapter originally appeared as: Moyerbrailean, G. A., Richards, A. L., Kurtz, D., Kalita,
C. A., Davis, G. O., Harvey, C. T., et al. (2016). High-throughput allele-specific expression across 250
environmental conditions. Genome Research, 26(12).
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asthma (CARRYER et al., 1950). Variation in gene expression has been found to play a
role in complex traits in additional studies as well (Li et al., 2015; Nicolae et al., 2010;
Raj et al., 2014; Grundberg et al., 2012). Supporting this hypothesis, we recently demon-
strated that genes with gene-environment (GxE) interactions at the molecular level are
highly enriched in GWAS Moyerbrailean et al. (2016a). More precisely, 49% of genes with
condition-specific allele specific expression in a study screening 250 cellular environments
were also found associated with GWAS traits. Beyond looking at gene expression,it is
well known that many enhancers are controlled by external stimuli (Hurtado et al., 2011;
Biddie et al., 2011; Hah et al., 2013; Shlyueva et al., 2014). However, few studies have
investigated the effect of external stimuli on regulatory regions using high-throughput re-
porter assays (Shlyueva et al., 2014; Vockley et al., 2016), and none have investigated the
allele specific effects.
Applying GEMMA (genome wide efficient mixed model association) using conditional
allele specific expression (cASE) (Moyerbrailean et al., 2016a) or eQTLs (Wen et al., 2015;
Consortium et al., 2015) we were able to calculate enrichment (heritability) for 18 complex
traits from GWAS. The highest values for cASE were observed for blood total cholesterol
level (TC) (9.7-fold), triglycerides (TG) (7.9-fold), and for mean corpuscular hemoglobin
levels (MCH) (8.6-fold). We additionally profiled five of the environmental conditions
from Moyerbrailean et al. (2016a) with very large gene expression changes for transcrip-
tion factor binding activity. This was accomplished at a genome-wide scale by ATAC-seq,
which utilizes the Tn5 transposase to fragment and tag accessible DNA. We further mod-
eled the Tn5 cleavage pattern “footprint ”of transcription factors with known motifs with
Centipede to identify bound binding sites. From our analyses we were able to characterize
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9,263 (dexamethasone), 2,615 (copper), and 2,115 (selenium) regions that have differ-
entially accessible regions (FDR<10%) in response to treatment. Using BiT-STARR-seq (a
high throughput allele-specific reporter assay (Kalita et al., 2018b)) with treatment we
then further validated these gene by environment (GxE) effects for specific variants. We
were able to identify thousands of ASE (FDR<10%) with retinoic acid (1,939), dexam-
ethasone (938), selenium (3,790), and caffeine (3,089).
Our results demonstrate that ATAC-seq together with an improved footprint model and
BiT-STARR-seq are excellent tools for rapid profiling of transcription binding factor activ-
ity to study cellular regulatory response to the environment and molecular mechanisms
underlying GxE.
Methods
Analysis of heritability enrichment using GEMMA
To run GEMMA (Zhou and Stephens, 2012, 2014) we partitioned SNPs genome wide
to create a category file. Each SNP was assigned to one of the following categories for
the cASE analysis: cASE (genic regions with conditional allele specific expression) or iASE
(genic regions with induced allele specific expression), ASE (genic regions with allele spe-
cific expression), Other Genic (genic regions that do not fall into any of the categories
above) and Intergenic (greater than 100kb from any gene). Each SNP was assigned to one
of the following categories for the eQTL analysis: eQTL (genic regions with eQTL), Other
Genic (genic regions that do not contain an eQTL) and Intergenic (greater than 100kb
from any gene). We then used GEMMA to compute the SNP correlations among different
categories from a reference panel (502 individuals of European ancestry from the 1000
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genome project). This was followed by summing the Z2 statistics from the GWAS meta-
analysis within the categories. Finally, we computed the proportion of variance, and fold
enrichment of heritability explained by each category. A table of the results can be found
in Table 3.
ATAC-seq data collection
The lymphoblastoid cell line (LCL) GM18508 was purchased from Coriell Cell Repos-
itory. LCLs were cultured in serum containing charcoal-stripped FBS and treated for 6
hours with 1µM selenium, dexamethasone or copper as described in Moyerbrailean et al.
(2016a). Cells were also cultured in parallel with the vehicle control (water or ethanol
(1 ml in 10,000 ml), to represent the solvent used to prepare the treatment. We then fol-
lowed the protocol by Buenrostro et al. (2013) to lyse 25,000-100,000 cells and prepare
ATAC-seq libraries, with the exception that we used the Illumina Nextera Index Kit (Cat
#15055290) in the PCR enrichment step. Individual library fragment distributions were
assessed on the Agilent Bioanalyzer and pooling proportions were determined using the
qPCR Kapa library quantification kit (KAPA Biosystems). Library pools were run on the Il-
lumina NextSeq 500 sequencer in the Luca/Pique-Regi laboratory. Barcoded libraries from
three ATAC-seq samples, performed with 25,000, 50,000 and 75,000 cells, were pooled
and sequenced on multiple sequencing runs for 100M 38bp PE reads.
ATAC-seq preprocessing and differential chromatin accessibility
Reads were aligned to the reference human genome hg19 using bwa mem (Li and Durbin
(2009) http://bio-bwa.sourceforge.net). Reads with quality <10 and without proper
pairs were removed using samtools (http://github.com/samtools/).
To identify differentially accessible regions, we used DESeq2 (Love et al., 2014) (R ver-
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sion 3.2.1, DESeq2 version 1.8.1). We separated the genome into 300bp regions and
coverageBed was used to count reads in these regions. Tiles were only included if they
contained the top 5% of read depths excluding those which were greater than 99.995% of
read depths. These counts were then utilized in DESeq2 using the following model:
Gene expression ∼ treatment
Yjn =
∑
t
βMjtMtn
(0.10)
where Yjn represents the internal DEseq mean accessibility parameter for region j and
experiment n, Mn is the treatment indicator (control or treatment), and βMjt parameter is
the treatment effect. Regions that changed following treatments were defined with BH
FDR < 10%.
Transcription factor binding footprints, and differential binding analysis
To detect which transcription factors motifs have footprints in each condition we adapted
Centipede in two ways: i) we use the fragment length information contained in the ATAC-
seq in the footprint model, and ii) we also developed a new test to detect global shifts in
footprints for each TF motif to reveal which factors may be activated in each condition.
As in Centipede we need to start from candidate binding sites a given motif model.
For each transcription factor we scan the entire human genome (hg19) for matches to its
DNA recognition motif using position weight matrix (PWM) models from TRANSFAC and
JASPAR as previously described (Pique-Regi et al., 2011). Then for each candidate location
l we collect all the ATAC-seq fragments which are partitioned into four binds depending
on the fragment length: 1) [39-99], 2) [100-139], 3) [140-179], 4) [180-250]. For each
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fragment, the two Tn5 insertion sites were calculated as the position 4bp after the 5′-end in
the 5′ to 3′ direction. Then for each candidate motif, a matrix X was constructed to count
Tn5 insertion events: each row represented a sequence match to motif in the genome
(motif instance), and each column a specific cleavage site at a relative bp and orientation
with respect to the motif instance. We built a matrix {Xl}4l=1 for each fragment length bin,
each using a window half-size S=150bp resulting in (2× S +W )× 2 columns, where W is
the length of the motif in bp.
First, we fit the Centipede model in a subset of instances to determine which motifs
have active binding (i.e. show footprints) with a Bonferroni′s corrected p-value of p <
0.05. The statistical significance is assessed by calculating a Z-score corresponding to the
PWM effect in the prior probability in the Centipede′s logistic hierarchical prior. Then
we used Centipede and motif instances with posterior probabilities higher than 0.99 to
denote locations where the transcription factors are bound. To determine which TF were
active in the first step, we calculate a Z-score corresponding to the PWM effect in the
prior probability in Centipede′s logisic model and we determined as active those that had
a Bonferroni corrected p<0.05. The Z-score corresponds to the β parameter in:
log
(
πl
1− πl
)
= α + β PWMscore l (0.11)
where πl represent the prior probability of binding in Centipede′s model in motif location
l. In the second step, we first trained Centipede assuming that the footprint was bound
in two conditions. Then, we fixed the model parameters and generated a liklihood ratio
and posterior probability πtl for each condition t separately and for each site l. To detect
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if the footprint was more active in one of the two conditions, we fit a logistic model that
included an intercept for each condition ( α and δ), the PWM effect β, and PWM times the
treatment effect γ :
log
(
πl
1− πl
)
= αx(1− It) + βx PWMscore l + δxIt + γx(Itx PWMscore l) (0.12)
where It is an indicator variable that takes the value 1 if t = “treatment ”and 0 if t =
“control ”. We then calculated a Z-score for the interaction effect γ, corresponding to the
evidence for condition specific binding.
BiT-STARR-seq oligo preparation
The Oligo library was taken from a plasmid pool of previous oligos used in Kalita et al.
(2018b). Extraction of the insert was carried out using Phusion High-Fidelity PCR Master
Mix with HF Buffer (NEB) and primers [F_transposase and R_transposase] (Table 2) with
cycling conditions: 98◦C for 30s, followed by 4 cycles of 98◦C for 10s, 50◦C for 30s, 72◦C
for 60s, followed by 6 cycles of 98◦C for 10s, 65◦C for 30s, 72◦C for 60s, followed by 72◦C
for 5 min. 8 samples of the template plasmid pool each with approximately 250ng of DNA
were used. The PCR product was run on a 2% agarose gel, extracted and purified with the
NucleoSpin Gel and PCR Clean-Up Kit (Clontech).
Table 2: Primers used in BiT-STARR-seq.
Primer Sequence
STARRseqP_F_SH TCTCCGAGCCCACGAGACGTCGACGAATTCGGCC
STARRseqP_R_SH ATCTGACGCTGCCGACGACCGGTGCATGCTCTA
F_transposase TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
R_transposase GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG
F_trans_short TCGTCGGCAGCGTCAGAT
I2.1 CAAGCAGAAGACGGCATACGA
Nextera_i7_10N CAAGCAGAAGACGGCATACGAGATRDHBVDHBVDGTCTCGTGGGCTCGG
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Cloning Regulatory regions into the STARR-seq Human plasmid
STARR-seq Human plasmid (Arnold et al., 2013) (addgene #71509) was linearized us-
ing CloneAmp HiFi PCR Premix (Clontech), primers [STARRseqP_F_SH and STARRseqP_R_SH],
and 35 cycles of 98◦C for 10s, 60◦C for 15s, and 72◦C for 5s. The PCR product was purified
on a 1% agarose gel as described above. Inserts were cloned into the linear plasmid using
standard NEBuilder HiFi DNA Assembly Master Mix cloning protocol. Clones were trans-
formed into MegaX DH10B electrocompetent cells (Thermo Fisher Scientific) in a total of
2 reactions. These reactions were pooled and grown overnight in 400ml LB at 37◦C in a
shaking incubator. DNA was extracted using Endofree maxiprep kit (QIAgen).
Transfection of LCL library
Previous studies (Muerdter et al., 2017; Huerfano et al., 2013) have found that trans-
fection, especially from nucleofection, can lead to activation of IFN-1 response, which may
complicate comparison of enhancer activities between different cell types. In our study de-
sign, allelic effects are measured and contrasted within the same cell type, thus any trans-
effect is inherently controlled. Furthermore, in LCLs the immune response is already acti-
vated because of EBV transformation. DNA library was transfected into LCLs (GM18507)
using standard nucleofection protocol, program DS150, 3µg of DNA and 7.5 × 106 cells.
For each of 3 biological replicates (from independent cell culture growths), we used 12 cu-
vettes, each set of 4 were pooled and plated. Each set was then treated with either control
or treatment (1 control and 2 treatments total per experiment). Treatments concentrations
used were as in Moyerbrailean et al. (2016a). Cells were incubated at 37◦C and 5% CO2 in
RPMI1640 with 15%FBS and 1% Gentamycin for 24h. Cell pellets were then lysed using
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RLT lysis buffer (QIAgen), and cryopreserved at -80◦C.
Library preparation
RNA-libraries. Thawed lysates were split in three aliquotes and total RNA was isolated
using RNeasy Plus Mini Kit (QIAgen). Poly-Adenylated RNA was selected using Dynabeads
mRNA Direct Kit (Ambion) using the protocol for total RNA input. RNA was reverse tran-
scribed to cDNA using Superscript III First-Strand Synthesis Supermix kit (ThermoFisher)
with primer [Nextera_i7_10N] and following the manufacturer′s protocol with the addi-
tion of RNase treatment for 30 min. cDNA technical replicates were pooled and SPRI
Select beads (Life Tech) were used for purification and size selection at a ratio of 0.9X.
PCR Library Enrichment was performed using a nested PCR protocol. For the first round
of PCR we used Phusion High-Fidelity PCR Master Mix with HF Buffer (NEB) and primers
[F_trans_short and Illumina2.1] with cycling conditions: 98◦C for 30s, followed by 15 cy-
cles of 98◦C for 10s, 72◦C for 15s, followed by 72◦C for 5 min. PCR product was purified
on a 2% agarose gel as described above. The nested PCR used Phusion High-Fidelity PCR
Master Mix with HF Buffer (NEB) and primers [fixed N5xx adapter (Illumina) (unique per
each library replicate) and Illumina2.1] with cycling conditions: 98◦C for 30s, followed by
5 cycles of 98◦C for 10s, 72◦C for 15s, followed by 72◦C for 5 min. In a side quantitative
real-time PCR reaction, 5µL of PCR product, 10X SYBR Green I, and the same primers and
master mix were run in conditions: 98◦C for 30s, 30 cycles of 98◦C for 10s, 63◦C for 30s,
and 72◦C for 60s. To determine the number of PCR cycles needed to reach saturation, we
plotted linear Rn versus cycle and determined the cycle number that corresponds to 25%
of maximum fluorescent intensity on the side reaction (Buenrostro et al., 2013). The PCR
product was purified on a 2% agarose gel as described above.
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DNA-libraries. We prepared 5 replicates of the DNA library using the PCR protocol
as described in (Buenrostro et al., 2013) except using NEB Next 2x Master mix, primers
[fixed N5xx adapter (Illumina) (unique per each library replicate) and Nextera_i7_10N]
and 30ng of input plasmid DNA. Cycling conditions were: initial denaturation at 72◦C for
5 min, followed by 5 cycles of 98◦C for 10s, 63◦C for 30s, and 72◦C for 60s. PCR product
was purified on a 2% agarose gel using Qiaquick gel extraction kit (Qiagen).
Library Sequencing
Pooled RNA and DNA libraries were sequenced on the Illumina Nextseq500 to generate
125 cycles for read 1, 30 cycles for read 2, 8 cycles for the fixed multiplexing index 2 and
10 cycles for index 1 (variable barcode).
Data Processing
Reads were mapped using the Hisat2 aligner (Kim et al., 2015), using the 1Kgenomes
snp index so as to avoid reference bias. First we removed variants whose UMI was not
possible to be present, given the UMI pattern selected. We then ran UMItools (Smith
et al., 2017) using standard flags, as well as a q20 filter. We then ran the deduplicated
files through mpileup using a bed file of our full SNP list, the -t DP4, -g, and -d 1000000.
Counts filters were as in Kalita et al. (2018b). To identify SNPs with allele-specific effects,
we applied QuASAR-MPRA (Kalita et al., 2018a), where for each SNP the reference and
alternate allele counts were compared to the DNA proportion. QuASAR-MPRA results from
each replicate were then combined for each treatment (or control) using the fixed effects
method, and corrected for multiple tests using BH procedure (Benjamini and Hochberg,
1995).
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Results
Gene-by-Environment interactions and Complex Traits
From previous work in our lab, we characterized genetic effects on the transcriptional
response to 50 treatments in 5 cell types and found that genes with a transcriptional re-
sponse to environmental perturbations showed 7-fold higher odds of being found in GWAS.
To investigate the role of GxE in complex traits directly, we analyzed per SNP heritability
for 18 complex traits using Genome-wide Efficient Mixed Model Association (GEMMA)
(Zhou and Stephens, 2012, 2014). Similar to the LD-score regression method that par-
titions heritability estimates across SNPs functional categories (Gusev et al., 2014), we
contrasted SNPs in genes with condition specific ASE, genes with ASE, genes without ASE,
and inter-genic regions (Table 3). eQTL studies in particular have been successful and
widely applied in identifying genomic regions associated with gene expression in various
tissues and conditions (Dimas et al., 2009; Maranville et al., 2011; Melé et al., 2015; Nica
et al., 2011). We therefore additionally contrast eGenes, genes without eQTLs, and in-
tergenic regions, using both eQTLs fine-mapped in (Wen et al., 2015) and GTEx eQTLs
(Consortium et al., 2015). The per SNP heritability for each of these categories is then
compared to the genome average. A higher value of per SNP heritability for one of these
categories indicates a higher number of causal SNPs, higher effect sizes or both in that
category.
We found that the per SNP heritability estimate for SNPs in genes with ASE is 11.1 times
higher than the genome average for high-density lipoprotein (HDL). For 13 of the 18 traits
analyzed, per SNP heritability estimates for SNPs in genes with cASE, iASE, or ASE were
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significantly higher than the genome average. For 7 of these, the cASE and iASE category
estimates were even higher than any other partition (Figure 14A), thus indicating that
GxE for these traits are particularly relevant. The highest values for cASE and iASE were
observed for blood total cholesterol level (TC) (9.7-fold), triglycerides (TG) (7.9-fold), and
for mean corpuscular hemoglobin levels (MCH) (8.6-fold). There is high enrichment for
GTEx eGenes in bone mineral density (femur) in stomach tissue (enrichment=15, Figure
14C). GTEX eGenes do however show similar enrichment patterns across tissues, likely
due to many eQTLs being shared between tissues. LCL eQTLs fine-mapped in Wen et al.
(2015) show high enrichment for bone mineral density (spine) (LSBMD) (enrichment=7,
Fig 14B). Overall, these results suggest an important role for GxE in a large number of
traits.
Table 3: GEMMA per SNP heritability estimates relative to the genomic average. Shown for each GWAS trait tested (see Table
5) are the estimates for cASE/iASE (SNPs in genic regions with cASE or iASE), ASE (SNPs in genic regions with ASE), No ASE (SNPs
in genic regions without ASE) and Intergenic (SNPs farther than 100kb from any gene). PVE: proportion of variance in phenotypes
explained.
GWAS Trait Category PVE Std Err σ2 Std Err Enrichment Std Err
BMI cASE/iASE 0.0003 0.0001 5.96E-09 2.17E-09 0.9697 0.3819
BMI ASE 0.0026 0.0010 1.68E-08 6.11E-09 2.7306 0.9696
BMI Intergenic 0.0021 0.0006 5.69E-09 1.50E-09 0.9260 0.2757
BMI No ASE 0.0267 0.0036 5.82E-09 7.81E-10 0.9469 0.0407
CD cASE/iASE 0.0005 0.0007 8.60E-09 1.43E-08 0.0957 0.1619
CD ASE 0.0229 0.0032 1.45E-07 2.03E-08 1.6199 0.2546
CD Intergenic 0.0004 0.0067 9.88E-10 1.81E-08 0.0110 0.2015
CD No ASE 0.4402 0.0314 9.60E-08 6.84E-09 1.0687 0.0169
FG cASE/iASE 0.0000 0.0002 5.83E-10 3.86E-09 0.0847 0.5609
FG ASE 0.0002 0.0006 1.56E-09 4.08E-09 0.2267 0.5973
FG Intergenic -0.0014 0.0009 -3.78E-09 2.56E-09 -0.5488 0.3597
FG No ASE 0.0365 0.0070 7.99E-09 1.52E-09 1.1616 0.0364
FNBMD cASE/iASE 0.0013 0.0004 2.42E-08 6.73E-09 5.1713 2.6679
FNBMD ASE 0.0028 0.0011 1.76E-08 6.97E-09 3.7533 2.3087
FNBMD Intergenic -0.0092 0.0015 -2.50E-08 4.02E-09 -5.3267 2.3578
FNBMD No ASE 0.0294 0.0109 6.41E-09 2.37E-09 1.3671 0.1246
HB cASE/iASE 0.0025 0.0003 4.86E-08 4.93E-09 6.7590 0.0150
HB ASE 0.0001 0.0006 6.81E-10 3.83E-09 0.0946 0.5336
HB Intergenic -0.0053 0.0008 -1.43E-08 2.19E-09 -1.9883 0.3669
HB No ASE 0.0398 0.0062 8.67E-09 1.34E-09 1.2058 0.0297
HDL cASE/iASE 0.0013 0.0002 2.57E-08 4.24E-09 2.6991 0.5198
HDL ASE 0.0166 0.0029 1.06E-07 1.81E-08 11.1082 1.8199
HDL Intergenic -0.0059 0.0006 -1.61E-08 1.59E-09 -1.6912 0.2039
HDL No ASE 0.0371 0.0067 8.09E-09 1.46E-09 0.8505 0.0593
HEIGHT cASE/iASE 0.0017 0.0001 3.18E-08 2.84E-09 1.3101 0.1387
HEIGHT ASE 0.0109 0.0008 6.91E-08 4.91E-09 2.8493 0.2311
HEIGHT Intergenic -0.0080 0.0007 -2.17E-08 1.80E-09 -0.8942 0.0718
Continued on next page...
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Table 3 – continued from previous page
GWAS Trait Category PVE Std Err σ2 Std Err Enrichment Std Err
HEIGHT No ASE 0.1205 0.0065 2.63E-08 1.41E-09 1.0854 0.0091
LDL cASE/iASE 0.0021 0.0004 3.96E-08 6.75E-09 5.8858 2.0932
LDL ASE 0.0044 0.0009 2.81E-08 5.89E-09 4.1724 1.6154
LDL Intergenic -0.0043 0.0008 -1.18E-08 2.24E-09 -1.7451 0.3600
LDL No ASE 0.0327 0.0116 7.11E-09 2.53E-09 1.0563 0.0593
LSBMD cASE/iASE 0.0030 0.0005 5.79E-08 1.03E-08 13.8333 6.5121
LSBMD ASE 0.0029 0.0012 1.86E-08 7.65E-09 4.4363 2.8557
LSBMD Intergenic -0.0074 0.0016 -2.01E-08 4.39E-09 -4.7997 2.3134
LSBMD No ASE 0.0231 0.0110 5.04E-09 2.40E-09 1.2022 0.1098
MCH cASE/iASE 0.0091 0.0007 1.73E-07 1.34E-08 8.6428 0.3575
MCH ASE 0.0007 0.0009 4.71E-09 5.99E-09 0.2355 0.3093
MCH Intergenic -0.0033 0.0013 -8.88E-09 3.47E-09 -0.4442 0.1560
MCH No ASE 0.0968 0.0123 2.11E-08 2.68E-09 1.0552 0.0164
MCHC cASE/iASE 0.0005 0.0002 9.88E-09 4.47E-09 -1.2357 0.6014
MCHC ASE -0.0003 0.0006 -1.91E-09 3.85E-09 0.2395 0.4845
MCHC Intergenic -0.0039 0.0008 -1.06E-08 2.17E-09 1.3290 0.3229
MCHC No ASE -0.0376 0.0047 -8.19E-09 1.03E-09 1.0251 0.0302
MCV cASE/iASE 0.0063 0.0005 1.21E-07 9.74E-09 5.8436 0.3254
MCV ASE 0.0019 0.0007 1.22E-08 4.50E-09 0.5892 0.2407
MCV Intergenic -0.0036 0.0011 -9.80E-09 2.88E-09 -0.4737 0.1246
MCV No ASE 0.1023 0.0102 2.23E-08 2.23E-09 1.0774 0.0138
MPV cASE/iASE 0.0032 0.0005 6.19E-08 9.40E-09 2.9909 0.6316
MPV ASE 0.0251 0.0039 1.60E-07 2.46E-08 7.7145 1.4648
MPV Intergenic -0.0114 0.0017 -3.09E-08 4.66E-09 -1.4916 0.2313
MPV No ASE 0.0899 0.0153 1.96E-08 3.34E-09 0.9475 0.0524
PCV cASE/iASE 0.0019 0.0003 3.60E-08 5.12E-09 6.1117 0.9515
PCV ASE -0.0015 0.0006 -9.42E-09 3.90E-09 -1.5979 0.7217
PCV Intergenic -0.0072 0.0009 -1.94E-08 2.39E-09 -3.2921 0.6572
Continued on next page...
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Table 3 – continued from previous page
GWAS Trait Category PVE Std Err σ2 Std Err Enrichment Std Err
PCV No ASE 0.0372 0.0057 8.11E-09 1.23E-09 1.3761 0.0595
PLT cASE/iASE 0.0036 0.0003 6.83E-08 6.25E-09 3.5299 0.3717
PLT ASE 0.0119 0.0013 7.54E-08 8.28E-09 3.8947 0.4394
PLT Intergenic -0.0089 0.0007 -2.40E-08 1.99E-09 -1.2390 0.1022
PLT No ASE 0.0934 0.0064 2.04E-08 1.39E-09 1.0520 0.0183
RBC cASE/iASE 0.0015 0.0003 2.87E-08 5.11E-09 1.8908 0.3775
RBC ASE 0.0004 0.0007 2.29E-09 4.56E-09 0.1509 0.3031
RBC Intergenic -0.0033 0.0010 -9.03E-09 2.78E-09 -0.5939 0.1727
RBC No ASE 0.0800 0.0084 1.74E-08 1.84E-09 1.1472 0.0188
TC cASE/iASE 0.0048 0.0005 9.12E-08 9.10E-09 9.6485 1.8248
TC ASE 0.0043 0.0009 2.73E-08 5.69E-09 2.8829 0.8570
TC Intergenic -0.0063 0.0007 -1.69E-08 2.02E-09 -1.7925 0.2413
TC No ASE 0.0460 0.0104 1.00E-08 2.27E-09 1.0614 0.0358
TG cASE/iASE 0.0037 0.0005 7.06E-08 9.64E-09 7.9232 0.0172
TG ASE 0.0152 0.0034 9.67E-08 2.18E-08 10.8507 2.8737
TG Intergenic -0.0062 0.0008 -1.68E-08 2.04E-09 -1.8806 0.3053
TG No ASE 0.0333 0.0098 7.26E-09 2.13E-09 0.8149 0.0807
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Figure 14: Integration with GWAS. GEMMA per SNP heritability estimates relative to the genomic average for cASE (SNPs in genic
regions with cASE or iASE), ASE (SNPs in genic regions with allele specific expression), Other Genic (SNPs in genic regions) and
Intergenic (SNPs farther than 100kb from any gene). Only significant enrichment values are reported, with darker tone of purple
indicating higher enrichment odds ratio relative to the genome average. B) GEMMA fold enrichment results for LCL eQTLs fine-mapped
in Wen et al. (2015) compared to ELSE (genic regions) and OTHER (greater than 100kb from any gene). Error bars are 2x the SE.
C) GEMMA Fold enrichment results for GTEx reported significant eGenes compared to ELSE (genic regions) and OTHER (greater than
100kb from any gene). Values shown are fold enrichments. Non significant results (based on 2SE) are in grey.
Environmental exposures change chromatin accessibility
While gene expression changes in response to the environment have been widely stud-
ied, there has been little exploration into changes at the chromatin level. Based on tran-
scriptional responses to 50 environmental perturbations (Moyerbrailean et al., 2016a) in 5
cell types (250 conditions), we chose 3 treatments (dexamethasone, copper, and selenium)
that the cells had a strong response to. We then used ATAC-seq to map condition specific
regulatory regions and variants with allele specific hypersensitivity in LCLs with these
treatments and their respective controls (water and ethanol). We identified differential ac-
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cessible regions (DeSeq) for each treatment, with the majority found with dexamethasone
(9,263 at FDR 10%), followed by copper (2,615), and selenium (2,115) (Figure 15A).
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Figure 15: Differential hypersensitive ATAC-seq. Log transformed p-values of ATAC-seq genomic tiles measured for differential
deviation of dexamethasone, copper, and selenium from the control. B) ATAC-seq footprint for CRE in copper treated vs control LCLs.
Venn diagram shows the number of bound sites in treated vs control. C) ATAC-seq footprint for CRE in dexamethasone treated vs
control LCLs. Venn diagram shows the number of bound sites in treated vs control.
ATAC-seq data along with sequence-based transcription factor motif models can be
further analyzed to identify the transcription factors involved in response to treatment,
using Centipede (Pique-Regi et al., 2011) to perform footprinting analysis. By identifying
the relevant TFs, we can identify the mechanisms behind many common traits. Using
Centipede′s hierarchical prior, we then did a likelihood ratio test for condition-specific
TF activity. For this, we fit the two conditions (treatment and control) simultaneously
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and extended Centipede hierarchical prior to detect factors with across all genome has a
change in activity. We identified about 100 TF footprints each condition, with a subset
then being condition specific (Table 4). TFs with the CRE motif, for example, were found
to have depleted binding sites after treating with copper (p < 0.001), while in Dex there is
no change (p > 0.13, Figure 15). We can see a decrease of binding sites, but also bound
sites would show a weaker footprint in these aggregate plots which is indicative of less
binding.Table 4: Number of identified factors/differential factors from ATAC-seq in LCLs.
Treatment ActiveFactors
Diff.
Active (p<0.005)
Dexamethasone 171 26
Copper 91 19
Selenium 147 18
Ctrl 1 (vs. Ctrl 2) 124 0
Identifying genetic variants showing allele specific effects to environmental pertur-
bation
To identify GxE that may explain inter-individual differences in disease risk conditional
on specific environmental exposures, we used a modified version of BiT-STARR-seq. For
this we used the same oligo library described in Kalita et al. (2018b), cloned now into the
STARR-seq human plasmid (Arnold et al., 2013) (now 48,958 constructs) and tested in
LCLs in triplicate. We selected the treatments dexamethasone, retinoic acid, selenium, and
caffeine as LCLs showed the greatest response to these in previous work (Moyerbrailean
et al., 2016a). We first assessed the extent of ASE in different cellular environments, using
QuASAR-MPRA (Kalita et al., 2018a) to calculate the beta estimate for the allelic ratio and
its standard error in each replicate. We then meta-analyzed by treatment. We successfully
identified ASE in each condition, with the largest number of significant ASE (FDR 10%) in
selenium (3,790) (Figure 16).
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Figure 16: ASE in treatments identified from BiT-STARR-seq. A) QQplot of ASE p-values from QuASAR-MPRA for each condition
tested. B) QQ plot depicting the p-value distributions from testing for ASE using QuASAR-MPRA, overlapping with DARs identified in
ATAC-seq.
To then test the hypothesis that differential accessibility is the mechanism driving the
conditional ASE, we looked for enrichment of the DARs identified through ATAC-seq with
the ASE results (matching by treatment). We found a much farther departure from the null
for the ASE p-values from BiT-STARR-seq in DARs as compared to the overall distribution
(Figure 16B). When we narrow this down to footprints, there is enrichment for ASE (from
BiT-STARR-seq) in TF footprints (from the ATAC-seq data) matched by treatment, in both
dexamethasone and selenium (Figure 17). For example, we find enrichment for ASE in
CNOT3 footprints (which is involved in early b-cell dev. (Inoue et al., 2015)) when LCLs
are treated with dexamethasone. While we lack a good footprint model for GR, we can
look for downstream targets. In an RNA-seq study done in our lab, we find that CNOT3 is
downregulated in response to dexamethasone in LCLs (Moyerbrailean et al., 2016a). We
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therefore successfully capture downstream targets of GR activation. CNOT3 has also been
linked to repression of other nuclear receptors (ie/Erα) (Winkler et al., 2006).
Figure 17: Enrichment for ASE in TF footprints matched by treatment. Barplot showing the odds ratio (y-axis) from Fisher′s test
for ASE in the TF footprint from ATAC-seq (x-axis) in dexamethasone (left) and selenium (right). * indicates enriched, ** indicates
significantly enriched after Bonferroni correction. Error bars indicate the CI from the Fisher′s test.
Discussion
In this study, we analyzed heritability, chromatin accessibility, and regulatory variants
with environmental exposures to in-vitro treatments. We found strong enrichment for
variants affecting GxE in many complex traits using ASE in RNA-seq and eQTLs from two
different studies. These data confirm the interaction of genetics and the environment
for GWAS and will aid future experiments by highlighting environmental variables that
should be considered in any complex trait studies. By analyzing regulatory regions and
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the variants within, in response to environmental stimuli, we can begin to understand the
impact of compounds to which we are daily exposed.
While the treatments investigated in this study cause significant changes in gene ex-
pression, chromatin accessibility, and allelic expression, they act through varied path-
ways. Dexamethasone and retinoic acid are steroid hormones whose action as an anti-
inflammatory factor at the molecular and transcriptional level has been well-established.
Caffeine has been identified as inhibiting the breakdown of cAMP and selenium has an im-
portant role as a cofactor. Copper is required for oxygen metabolism and has been linked to
decreased effector activities of B cells and neutrophils (Prohaska and Failla, 1993; Djoko
et al., 2015). However, the effect of these environments on heritability and the regula-
tory response has been less characterized. We have annotated footprints and treatment
response factors in LCLs. We were able to confirm that these regulatory regions affect ex-
pression in an allele specific manner when analyzing ATAC-seq DARs with BiT-STARR-seq.
Additionally, we confirm with dexamethasone that our approach identifies biologically rel-
evant response factors, as we found enrichment of a known downstream target (CNOT3)
of the glucocorticoid pathway for ASE. By using BiT-STARR-seq to investigate allelic ef-
fects, we are no longer limited to looking at naturally occurring variation, as seen in re-
QTL, conditional ASE, or conditional allele specific hypersensitivity studies. This therefore
represents a cost-effective approach to rapidly screen the phenotypic effect of genetic and
environmental factors in a variety of contexts. In combination with the computational
tools our lab has developed, this approach is a unique resource to functionally character-
ize genetic variants in specific cellular environment at an unprecedented and expandable
scale.
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CHAPTER 5 CONCLUSION
Genome-wide association studies (GWAS) have identified a large number of genetic
variants associated with disease as well as normal phenotypic variation for complex traits
such as height (Mailman et al., 2007). However, challenges remain in determining the
functional relevance of human DNA sequence variants (Ward and Kellis, 2012). GWAS
identify large regions of association and in general, cannot directly pinpoint the true
causative variant. Second, even after fine mapping, most variants are located in non-
coding regions making it difficult to infer mechanisms linking individual genetic variants
with the disease trait. In addition, we do not know under which environmental conditions
the sequence variants have a functional impact, and whether they become one of many
factors involved in complex phenotypes at the organismal level. Throughout this disser-
tation, I sought to address these problems and to develop methods to better study allele
specific effects and their link to complex phenotypes.
In Chapter 2, I used computational methods to predict causal GWAS variants, validated
a subset for ASE using a traditional reporter assay, and developed a method to identify
ASE in high throughput validations. Many high throughput reporter assays validated only
a small number of regulatory regions due to experimentally testing many regions with
only a small amount of prior expectation of activity. By computationally narrowing down
the regions likely to have an effect on expression, we were able to identify about 50% of
our predicted regions as being enhancer/repressor. Additionally, the rapid development
of MPRA and STARR-seq to screen regulatory regions meant that no one had taken the
time to develop a well-calibrated and powerful method to identify ASE in these studies.
QuASAR-MPRA was developed to tackle this problem, and we found it to be low in inflation
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(bias) and in every simulated condition (variance in the data, effect size of ASE, number of
replicates, and sequencing depth) it out performed the t-test (used previously in MPRA).
This method will continue to be useful as more researchers begin using high throughput
assays to identify allelic effects.
In Chapter 3 I develop a new modification of STARR-seq in order to streamline the
assay and improve power to detect ASE through the addition of an UMI. By spending the
effort to optimize the assay conditions, we make the assay easier for researchers to quickly
and efficiently validate regulatory variants of interest. One advantage to our approach is in
the synthesis of the oligos. This allows for testing any variant of interest, without relying
on natural variation so allowing for testing of rare variants which is not typically possible
in QTL studies. Another advantage is in adding the UMI after transfection of the oligos into
the cells. This avoids complexity bottlenecks in cloning, transformation, and transfection
efficiencies that often occur in MPRA. When these bottlenecks occur, researchers generally
greatly increase for example, the number of cells transfected, making the assay no longer
feasible for many researchers. The UMI also allows us to account for PCR duplicates in
the library preparation stage and so have increased power to detect ASE. Additionally,
by integrating BiT-STARR-seq with a high throughput allele-specific EMSA, we are able to
identify the mechanism behind many ASE variants.
Studying GxE in human studies is extremely difficult, so our approach of using an in-
vitro method and modeling molecular phenotypes is a useful alternative. Using GEMMA,
we were able to identify environments that were enriched for complex traits. This shows an
increased relevance for complex traits when using conditional allele-specific information,
which confirms the significance of GxE in complex traits. With ATAC-seq data we were able
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to identify differentially accessible regions, TF footprints, and differential TF footprints.
Integrating this data with BiT-STARR-seq, we were able to identify enrichment for these
differential chromatin accessibility regions with ASE.
Using the information generated through my research can lead to understanding the
genetic and molecular basis of inter-individual differences in complex traits. For instance,
genetic variants that cause altered gene expression can lead to development of these traits
at the organismal level. Consequently, it is important to not only identify true gene-
regulatory regions but also to test if specific genetic variants within these regions affect
gene expression. In addition to tightly regulating baseline gene expression levels, these
genetic and epigenetic controls determine the transcriptional response to external stimuli.
Together, in my research I′ve used integration of computational predictions with experi-
mental validation to identify allelic effects. This design is a useful approach to validate
the molecular mechanism for specific transcription factors, and link these to the context of
human health. We hope this work may lead to actionable therapies in the future.
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APPENDIX A
We integrated our Centipede footprint annotations into the combined models learned
in Pickrell (2014) for GWAS meta-studies corresponding to 18 traits (Table 5), using the
fgwas command line program. We assessed enrichment or depletion for footprint anno-
tations using the log2(enrichment) values, excluding any motifs whose 95% confidence
interval (CI) spanned zero. For each TF motif whose binding sites are either significantly
enriched or depleted for trait-associated SNPs (Figure 18), we examined the SNPs whose
posterior probability of association (PPA) with a trait had been increased by the addition of
our annotation. Overall we found 88 unique SNPs whose associations were strengthened
by our footprint annotations (Table 7).
Validating putative causal SNPs by reporter gene assays
From the 88 SNPs identified by the fgwas analysis, we considered GWAS-relevant effect-
SNPs located in active footprints in LCLs (the cell line used for transfection) and ranked
them on the Spearman correlation coefficient in Moyerbrailean et al. (2016b). We ini-
tially selected the top 25 SNPs with a positive correlation, but the assays for 4 of them
failed for several technical reasons (e.g., cloning step failed). To validate the predicted
allelic effects on gene expression for the remaining 21 SNPs, we first constructed inserts
containing the reference or alternate allele for each SNP of interest. Each region was am-
plified from genomic DNA extracted from LCLs (Coriell). Primers were designed using
the Infusion Clontech online primer design tool for inserts containing the SNP of interest
±100bp. Primers were ordered from IDT technologies. Inserts were amplified by PCR and
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pGL4.23 plasmid was linearized (inverse PCR) using Clontech Hi-fi PCR premix and follow-
ing the manufacturer’s instructions. PCR products and linearized plasmid were resolved
on agarose gel, excised and purified using Nucleospin gel extraction and PCR cleanup kit
(Clontech). Inserts were cloned into linearized pGL4.23 using the Infusion Cloning HD kit
(Clontech). Transformation was done using Stellar Competent cells (Clontech) and DNA
was extracted from selected colonies using the PureYield kit (Promega). The allelic status
and the absence of artifactual mutations of each clone was validated by Sanger sequencing
performed by Genewiz. Transfections were performed into GM18507 using the standard
protocol for the Nucleofector electroporation (Lonza). After 10 hours we measured Firefly
and Renilla (transfection control) luciferase activity using the Dual-Glo Luciferase Assay
Kit (Promega) on the GloMax instrument (Promega). Luciferase activity was measured for
up to 20 replicate experiments. We then used a t-test to identify significant differences
in the expression of the reporter gene, calculated by the ratio of the firefly to the renilla
activity, normalized to the ratio of the activity in the untransfected cells. We contrasted the
activity of each construct to the pGL4.23 vector, to assess enhancer/repressor activity of
each region. To evaluate allele-specific effects, we contrasted the activity of the reference
allele to the alternate allele for each region. These results are summarized in Table 8 and
in Figure 7.
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Table 5: Summary of GWAS meta analysis traits examined. Shown for each trait is the trait abbreviation and the citation for the
meta analysis study.
Abbreviation Trait Study
BMI Body mass index Speliotes, E.K., et al. (2010). Nat. Genet. 42, 937-948
CD Chron disease Jostins, L., et al. (2012). Nature 491, 119-124
FG Fasting glucose levels Manning, A.K., et al. (2012). Nat. Genet. 44, 659-669
FNBMD Bone mineral density (femur) Estrada, K., et al. (2012). Nat. Genet. 44, 491-501
HB Hemoglobin levels van der Harst, P., et al. (2012). Nature 492, 369-375
HDL HDL cholesterol levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
Height Height Lango Allen, H., et al. (2010). Nature 467, 832-838
LDL LDL cholesterol levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
LSBMD Bone mineral density (lumbar spine) Estrada, K., et al. (2012). Nat. Genet. 44, 491-501
MCH Mean red blood cell hemoglobin van der Harst, P., et al. (2012). Nature 492, 369-375
MCHC Mean corpuscular hemoglobin concentration van der Harst, P., et al. (2012). Nature 492, 369-375
MCV Mean red blood cell volume van der Harst, P., et al. (2012). Nature 492, 369-375
MPV Mean platelet volume Gieger, C., et al. (2011). Nature 480, 201-208
PCV Packed red blood cell volume van der Harst, P., et al. (2012). Nature 492, 369-375
PLT Platelet counts Gieger, C., et al. (2011). Nature 480, 201-208
RBC Red blood cell count van der Harst, P., et al. (2012). Nature 492, 369-375
TC Total cholesterol levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
TG Triglyceride levels Teslovich, T.M., et al. (2010). Nature 466, 707-713
Table 6: Factor binding sites enriched for GWAS SNPs. For each trait, factors whose binding sites are enriched for SNPs associated
with the trait are listed. Shown also are the lower and upper limits of the 95% confidence interval.
Available at http: // genome. grid. wayne. edu/ centisnps/ supp/
Table 7: SNPs associated with GWAS traits that fall in Centipede-predicted TF binding sites. PPA, Posterior probability of association
estimated by fgwas for each SNP. "Before" indicates the PPA from the base model, "after" indicates the PPA after adding footprint
annotations to the model. The p-values listed are derived from the z-scores that are used as input for fgwas.
Available at https: // doi. org/ 10. 1371/ journal. pgen. 1005875. s020
Table 8: Reporter gene assay results. For each of the SNPs tested, listed are the results for the reference allele (top) and the alternate
allele (bottom). Shown is the average and standard error (across replicates) of the firefly luciferase activity normalized to the renilla
luciferase activity, for each construct (Norm Expr) and for the pGL4.23 vector (Empty Vector). The last two columns are the t-test p-
values comparing the activity of the reference allele to the alternate allele (vs ref), and of each allele to the pGL4.23 vector (vs empty).
Underlined alleles indicate the allele predicted to have stronger binding.
Available at https: // doi. org/ 10. 1371/ journal. pgen. 1005875. s021
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M01608=DAL82
M01949=Ybr239c
M01572=MIG1
M00287=NF−Y
MA0060.1=NFYA
PBM0118=Elf4_RC
M00433=Hmx3 (Nkx5−1)
PBM0124=Elf4
M00016=E74A
M02032=SWI4
M01068=Zfp281
M01923=Rox1
M00664=STE12
M01597=Zfp281
M01180=SPL14
M00197=ABF1
M00698=HEB
M01621=SOK2
M01346=TGIF1
MA0019.1=Ddit3::Cebpa
M01883=IRF−4
M01181=Nkx3−2
M01550=Mbp1
PBM0023=/GR09/Mbp1
M00357=bZIP910
M00313=GEN_INI
M01917=Ynr063w
M01542=PBF1
M00720=CAC−binding protein
M01644=EDS1
M01030=Rim101p
M00241=Nkx2−5
M00459=STAT5B (homodimer)
M00355=PBF
M00063=IRF−2
M01609=SWI4
M00986=Churchill
M01538=Aro80
PBM0009=/GR09/Aro80
M00187=USF/E−Box
M01774=TBR2
M01653=HMGIY
M00361=CDC5
PBM0119=/EMBO10/Elk1_RC
PBM0129=/EMBO10/Elk1
M01888=Smad3
M00089=Athb−1
M01245=mTERF
M01641=RFX1
M01946=LYS14
M00332=Whn
M01175=CKROX
PBM0036=/GR09/Sfl1
M01461=EMX2
M01204=SPI−B
M02041=Spi−B
M01589=ERR2 (ESRRB)
M00932=Sp1
MA0141.1=Esrrb
M02043=SPI1 (PU.1)
MA0079.2=SP1
M01641=E2F
M01264=RFX1
M01125=Foxd3
M01124=TBX15
M01114=CDP CR1
M00104=SMAD
M00792=Nkx2−5
M00776=Oct−4 (POU5F1)
M00241=SREBP
MA0142.1=Oct−4 (POU5F1)
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FigureS20: Enrichment of transcription factorsmotifs fromfgwas. Shownare the log2(enrichment) valueswith95%
conf denceintervals for each factorwhosebindingsitesareenriched for SNPsassociatedwith thetraits inTable14. x-axis is
truncatedat10foreaseof display.
Figure 18: Enrichment of transcription factors motifs from fgwas. Shown are the log2(enrichment) values with 95% confidence
intervals for each factor whose binding sites are enriched for SNPs associated with the traits in Table 14. x-axis is truncated at 10 for
ease of display.
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A B
Figure 19: Association plots identifying SNPs in footprints. Log Bayes factor (top) and posterior probabilities (bottom) of association
to the indicated trait for all genetic variants in the regions containing rs4519508 and rs532436.
87
Figure 20: Association plots identifying SNPs in footprints from fgwas. For each SNP in Table 13, two plots show the log Bayes
factor (top) and posterior probabilities (bottom) of association to the indicated trait for all genetic variants in the region containing the
SNP. This Figure continues to next page . . .
.
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Figure 20 . . . continued from previous page
Figure 20 continues to next page . . .
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Figure 20 . . . continued from previous page
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Table 9: Annotations Used. Experimental and computational annotations used for overlap with the MPRA dataset.
Annotation Description Publication Source
ASH Variants with allele-specific hypersensi-
tivity (ASH) in DNase-seq data
Moyerbrailean et al
2016
genome.grid.wayne.edu/centisnps/
LCL dsQTLs Variants associated with DnaseI hyper-
sensitivity
Degner et al 2012 eqtl.uchicago.edu
GTEx eQTL Variants associated with gene expres-
sion changes
Consortium et al
2015
www.gtexportal.org
Effect-SNPs Variants predicted to affect TF binding Moyerbrailean et al
2016
genome.grid.wayne.edu/centisnps
GKM-svm Predicts the impact of SNPs on DNase
I sensitivity (dsQTLs) from gapped k-
mers
Lee et al 2015 www.beerlab.org/deltasvm/downloads
CATO Predicts the effect of SNPs on the en-
ergy of TF binding
Maurano et al 2015 Supplement Table
DeepSEA Deep learning-based algorithmic frame-
work for predicting the chromatin ef-
fects of sequence alterations
Zhou et al 2015 deepsea.princeton.edu/job/analysis/create
Table 10: QuASAR Results for LCLs. QuASAR p-values for MPRA LCL counts data. File is LCL_quasar_pval_comb.csv
Available at https: // academic. oup. com/ bioinformatics/ article/ 34/ 5/ 787/
4209990# supplementary-data
Table 11: QuASAR Results for HepG2. QuASAR p-values for MPRA HepG2 counts data. File is hepg2_quasar_pval.csv
Available at https: // academic. oup. com/ bioinformatics/ article/ 34/ 5/ 787/
4209990# supplementary-data
Table 12: Logistic Model predictions for LCLs. p-value results from running the logistic model. In all cases where scores had both
negative and positive values, absolute scores were used.
Predictor Estimate p-value
GKM-svm 1.11× 10−02 1.53× 10−09
Effect-SNP 2.75× 10−02 1.71× 10−15
LCL dsQTL 3.10× 10−02 1.46× 10−03
CATO 5.75× 10−01 2.48× 10−03
DeepSEA −4.41× 10−02 2.17× 10−02
GTEx lead SNP 7.35× 10−04 7.59× 10−01
Table 13: Logistic Model predictions for HepG2. p-value results from running the logistic model. In all cases where scores had both
negative and positive values, absolute scores were used.
Predictor Estimate p-value
GKM-svm −2.07× 10−04 6.57× 10−01
Effect-SNP 1.45× 10−02 1.18× 10−10
LCL dsQTL 1.37× 10−02 2.88× 10−02
CATO −8.51× 10−02 4.55× 10−01
DeepSEA −1.64× 10−02 7.95× 10−02
GTEx lead SNP −8.65× 10−06 9.95× 10−01
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Comparison to QuASAR
We compared our QuASAR-MPRA implementation to the original QuASAR method.
We show that while QuASAR may perform well when the DNA proportion distribution is
closely centered on 0.5, but not when the proportion is different than 0.5 (Figure 26).
While the average DNA proportion for this dataset is 0.499, the range is considerable
(0.014 to 0.974), so a method that can handle a wide range of DNA proportions is neces-
sary.
Reverse oligo results
Based on the genomics inflation values, the QuASAR test results in the lowest inflation.
The results provided in the main text are for the forward strand constructs but we obtain
very similar genomic inflation values in the reverse strand. However we only found 22
SNPs that were significant in both the forward and reverse orientations. This could be as
both directions are not equally sampled but it would be interesting to do a more detailed
analysis of the mechanism behind the differences seen between the two directions in the
future. QuASAR lambda is 1.17 LCL/ 0.76 HepG2, while the binomial test produces the
greatest inflation, with lambda values of 56.77 LCL/ 27.07 HepG2. Two tests previously
used in high throughput reporter assay, result in intermediate levels of inflation, between
these two extremes. A paired t-test with independent estimation of variance and Welch’s
adjustment, as in Tewhey et al., results in lambda values of 2.66 LCL/ 2.85 HepG2; while
Fisher’s exact test, as in (Vockley et al., 2015) results in lambda values of 38.74 LCL/ 9.95
HepG2. In addition, looking at genomic inflation values for only non-effect SNPs, QuASAR
lambda is 1.22 LCL/ 0.79 HepG2, the binomial test lambda is 53.18 LCL/ 22.60 HepG2,
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t-test lambda is 3.12 LCL/ 3.36 HepG2, and Fisher’s exact test lambda is 35.98 LCL/ 11.35
HepG2.
Figure 21: Comparing ASE testing methods in HepG2 from Tewhey et al. (2016). QQplot depicting the p-value distributions from
testing for ASE using four different methods in HepG2 for all SNPs (Left) or non-effect SNPs only (Right). λ measures genomic inflation
deviation from the uniform.
Figure 22: Validating experimental annotations in HepG2. QQ plot depicting the p-value distributions from testing for ASE using
QuASAR, overlapping with experimental genomic annotations in HepG2. An annotation enrichment p-value is reported next to their
labels, but only for those annotations that are significantly enriched for small QuASAR-MPRA p-values according to the logistic model
(see Methods).
Figure 23: Validating computational genomic annotations in HepG2. QQ plot depicting the p value distributions from testing for
ASE using QuASAR, overlapping with computational genomic annotations in HepG2. Effect-SNP scores have a threshold of < −3 or
> 3. CATO Maurano et al. (2015) prediction scores have a threshold of> 0.1. GKM-svm Lee et al. (2015a) gapped kmer sequence-based
computational method to predict the effect of regulatory variation has a threshold of < −6 or > 6. DeepSEA Zhou and Troyanskaya
(2015) predicts genomic variant effects at the variant position using deep learning-based algorithmic framework. The functional
significance predictions have a threshold of < 0.05.An annotation enrichment p-value is reported next to their labels, but only for those
annotations that are significantly enriched for small QuASAR-MPRA p-values according to the logistic model (see Methods).
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Figure 24: Identifying cell type effects in LCLs. QQ plot depicting the p-value distributions from testing for ASE using QuASAR,
overlapping with effect-SNP annotations in LCLs. LCL effect-SNPs (blue) are variants in TFs active in LCLs, HepG2 effect-SNPs (red)
are variants in TFs active in HepG2, LCL/HepG2 effect-SNPs (green) are variants in TFs active in LCLs or HepG2.
Figure 25: Identifying cell type effects in in HepG2. QQ plot depicting the p-value distributions from testing for ASE using QuASAR,
overlapping with effect-SNP annotations in HepG2. LCL effect-SNPs (blue) are variants in TFs active in LCLs, HepG2 effect-SNPs (red)
are variants in TFs active in HepG2, LCL/HepG2 effect-SNPs (green) are variants in TFs active in LCLs or HepG2.
Figure 26: Comparing QuASAR and QuASAR-MPRA ASE testing methods in LCLs. QQplot depicting the p-value distributions from
testing for ASE using QuASAR or QuASAR-MPRA in LCLs, SNPs separated by DNA proportion range to be either close to 0.5 or far away
from 0.5.
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APPENDIX B
Oligo selection and design
Tables 15, 16, 17 report the annotations we have considered with their sources and
Table (29, 25) includes the library composition. These included: SNPs predicted to al-
ter transcription factor binding in LCLs and HepG2 (CentiSNPs, (Moyerbrailean et al.,
2015)), LCL eQTLs fine-mapped in (Wen et al., 2015), liver eQTLs (Innocenti et al., 2011),
significant fgwas SNPs in transcription factor binding motifs for 18 complex traits (Moyer-
brailean et al., 2016b), significant fgwas SNPs for base models of functional annotations
for 18 complex traits (Pickrell, 2014), ASB SNPs, and strong enhancers with no predicted
ASB (regions with footprints containing SNPs that are not predicted to affect binding of
TFs) (Moyerbrailean et al., 2015). CentiSNP is an annotation that we recently developed
(Moyerbrailean et al., 2016b), and that uses the Centipede framework (Pique-Regi et al.,
2011) to integrate DNase-seq footprints with a recalibrated position weight matrix (PWM)
model for the sequence to predict the functional impact of SNPs in footprints. SNPs in
footprints “footprint-SNPs” are further categorized using Centipede hierarchical prior for
each allele as “CentiSNP” if the prior relative odds for binding are >20. FASTA sequences
with a window of 99 (on each side of the SNP) on the BED file were grabbed using se-
qBedFor2bit (Moyerbrailean et al., 2015), and 15bp matching sequencing primers used
for Illumina NGS were added to each end. This generates an oligo containing 200bp of
regulatory region with the SNP centered in the middle, with primers on both ends (Figure
27). Each regulatory region was designed to have two oligos: one for each of the alleles. A
second list of the FASTA sequences without the primer ends was generated to use as a cus-
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tom reference genome, then converted to fastq using fatofastq (UCSC genomics utilities).
The full SNP list was aligned to the hg19 genome with BWA mem (Li, 2013), removing
the regions that aligned with a quality score less than 20 (unique alignment probability
> 99%). The full SNP list was also aligned to the custom reference genome, and then
filtered for a quality score of 190. A total of 39,366 indexes were randomly generated to
match this pattern: RDHBVDHBVD. This sequence was chosen to limit the longest possible
polyACGT run at any position to 3 nucleotides, and avoid a G in the first and last position
(corresponding to a dark cycle on the Illumina NextSeq 500).
Oligo synthesis and amplification
DNA inserts 230bp long, corresponding to 200bp of regulatory sequence, were synthe-
sized by Agilent to contain the regulatory region and the SNP of interest within the first
150bp. We performed a first round of PCR using Phusion High-Fidelity PCR Master Mix
with HF Buffer (NEB) and primers [F_transposase and R_transposase] (Table 30) with cy-
cling conditions: 98◦C for 30s, followed by 4 cycles of 98◦C for 10s, 50◦C for 30s, 72◦C for
60s, followed by 6 cycles of 98◦C for 10s, 65◦C for 30s, 72◦C for 60s, followed by 72◦C for
5 min. This reaction was used to double strand the oligos and complete the sequencing
primers. The PCR product was run on a 2% agarose gel, extracted and purified with the
NucleoSpin Gel and PCR Clean-Up Kit (Clontech). A subsequent round of PCR amplified
the material using the same reaction as in the first round of PCR, but with cycling con-
ditions: 98◦C for 30s, followed by 15 cycles of 98◦C for 10s, 65◦C for 30s, 72◦C for 60s,
followed by 72◦C for 5min. The PCR product was purified as described above.
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Cloning Regulatory regions into pGL4.23
A recent study demonstrated that the ORI can be an active promoter in pGL4.23 plas-
mids and can function as a stronger promoter in the absence of other promoter sequences
(Muerdter et al., 2017). Here we used a design that includes a minimal promoter, thus
potentially missing some signal from the weakest enhancer sequences in our library. How-
ever, as we focus on allele-specific enhancer activity, the presence of a minimal promoter
in addition to the ORI, should affect both alleles similarly and should not induce false
positives in the allele-specific signal.
Plasmid pGL4.23 (Promega) was linearized using CloneAmp HiFi PCR Premix (Clon-
tech), primers [STARR_F_SH and STARR_R_SH], and 35 cycles of 98◦C for 10s, 60◦C for
15s, and 72◦C for 5s. The PCR product was purified on a 1% agarose gel as described
above. Inserts were cloned into the linear plasmid using standard Infusion (Clontech)
cloning protocol. Clones were transformed into XL10-Gold Ultracompetent Cells (Agilent)
in a total of 7 reactions. These reactions were pooled and grown overnight in 500ml LB at
37◦C in a shaking incubator. DNA was extracted using Endofree maxiprep kit (Qiagen).
Transfection of library
Previous studies (Muerdter et al., 2017; Huerfano et al., 2013) have found that trans-
fection, especially from nucleofection, can lead to activation of type 1 interferon response,
which may complicate comparison of enhancer activities between different cell types. In
our study design, allelic effects are measured and contrasted within the same cell type,
thus any trans-effect is inherently controlled. Furthermore, in LCLs the immune response
is already activated because of EBV transformation. DNA library was transfected into
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LCLs (GM18507) using standard nucleofection protocol, program DS150, 3µg of DNA and
7.5×106 cells. A total of 3 sets of transfections were done in triplicate cuvettes, then pooled.
We performed nine biological replicates of the transfection from 7 independent cell growth
cultures. After transfection, cells were incubated at 37◦C and 5% CO2 in RPMI1640 with
15%FBS and 1% Gentamycin for 24h. Cell pellets were then lysed using RLT lysis buffer
(Qiagen), and cryopreserved at -80◦C.
Library preparation
RNA-libraries. Thawed lysates were split in three aliquotes and total RNA was iso-
lated using RNeasy Plus Mini Kit (Qiagen). Poly-adenylated RNA was selected using Dyn-
abeads mRNA Direct Kit (Ambion) using the protocol for total RNA input. RNA was re-
verse transcribed to cDNA using Superscript III First-Strand Synthesis kit (ThermoFisher)
with primer [Nextera_i7_10N] and following the manufacturer′s protocol. cDNA technical
replicates were pooled and SPRI Select beads (Life Tech) were used for purification and
size selection at a ratio of 0.9X. PCR Library Enrichment was performed using a nested
PCR protocol. For the first round of PCR we used Phusion High-Fidelity PCR Master Mix
with HF Buffer (NEB) and primers [F_trans_short and Illumina2.1] with cycling condi-
tions: 98◦C for 30s, followed by 15 cycles of 98◦C for 10s, 72◦C for 15s, followed by 72◦C
for 5 min. PCR product was purified on a 2% agarose gel as described above. The nested
PCR used Phusion High-Fidelity PCR Master Mix with HF Buffer (NEB) and primers [fixed
N5xx adapter (Illumina) (unique per each library replicate) and Illumina2.1] with cycling
conditions: 98◦C for 30s, followed by 5 cycles of 98◦C for 10s, 72◦C for 15s, followed by
72◦C for 5 min. In a side quantitative real-time PCR reaction, 5µL of PCR product, 10X
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SYBR Green I, and the same primers and master mix were run in conditions: 98◦C for 30s,
30 cycles of 98◦C for 10s, 63◦C for 30s, and 72◦C for 60s. To determine the number of
PCR cycles needed to reach saturation, we plotted linear Rn versus cycle and determined
the cycle number that corresponds to 25% of maximum fluorescent intensity on the side
reaction (Buenrostro et al., 2013). The PCR product (Figure 27) was purified on a 2%
agarose gel as described above.
DNA-libraries. We prepared 7 replicates of the DNA library using the PCR protocol as
described in (Buenrostro et al., 2013) except using primers [fixed N5xx adapter (Illumina)
(unique per each library replicate) and Nextera_i7_10N] and 30ng of input plasmid DNA.
PCR product was purified on a 2% agarose gel as described above.
BiT-BUNDLE-seq
We used BiT-BUNDLE-seq, a new version of the BUNDLE-seq protocol (Levo et al.,
2015). Input DNA sequences were extracted from the BiT-STARR-seq DNA plasmid library
using the same PCR conditions as in preparing the DNA libraries, followed by purification
on a 2% agarose gel as described above. We used N-terminal GST-tagged, recombinant
human NFKB1 from EMD Millipore. The reaction buffer (0.15 M NaCl, 0.5 mM PMSF
[Sigma], 1 mM BZA [Sigma], 0.5X TE, and 0.16 µg/µL PGA [Sigma]) was incubated
at room temperature for 2 hours in low binding tubes (ThermoFisher). The tubes were
cooled for 30 min at 4◦C, and then 0.067 µg/µL BSA (Sigma) was added before adding
the NFKB1 protein. One hundred nanograms of DNA were then added, and the protein
and DNA were incubated for 1 h at 4◦C. Experiments were performed in triplicates for
each NFKB1 concentration.
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The reaction mix was run with 6µL Ficoll (Sigma) in a 7.5% Mini-PROTEAN TGX Pre-
cast 10-well Protein Gel (BIORAD) in cold 0.25X TBE buffer for 2 hours at 100V. The
gel was stained for 30 min with 3X GelStar (Lonza). Bound and unbound DNA bands
were excised under a blue light transilluminator. The DNA was eluted from the gel using
the QIAQuick Gel Extraction Kit with a User-Developed Protocol (Qiagen QQ05). The gel
slices were incubated in a diffusion buffer (0.5 M ammonium acetate, 10mM magnesium
acetate, 1mM EDTA, ph 8.0 [KD Medical]; 0.1% SDS [Sigma]) at 50◦C for 30 minutes.
The supernatant was then passed through a disposable plastic column containing packed,
siliconized glass wool [Supelco] to remove any residual polyacrylamide. Libraries were
then quantified and loaded on the NextSeq 500 for sequencing.
Library Sequencing
Pooled RNA and DNA libraries were sequenced on the Illumina Nextseq 500 to generate
125 cycles for read 1, 30 cycles for read 2, 8 cycles for the fixed multiplexing index 2 and
10 cycles for index 1 (variable barcode). Sequencing depth for each replicate can be found
in Table 31.
Data Processing
Reads were mapped using the HISAT2 aligner (Kim et al., 2015), using the 1Kgenomes
snp index so as to avoid reference bias. First we removed variants whose UMI was not
possible to be present, given the UMI pattern selected. We then ran UMItools (Smith et al.,
2017) using standard flags, as well as a q20 filter. We then ran the deduplicated files
through mpileup using a BED file of our full SNP list, the -t DP4, -g, and -d 1000000. DNA
reads were processed through a counts filter (on the summed replicates) of more than
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7 counts per SNP and at least one count for the reference and alternate alleles in either
direction. 50,609 SNPs in the DNA library were used as input to the RNA library. The RNA
library was processed following the same procedure as for the DNA library, except that the
counts filter required a count of >1 per SNP and at least one count for both reference and
alternate alleles. To identify SNPs with allele-specific effects, we applied QuASAR-MPRA
(?), where for each SNP the reference and alternate allele counts were compared to the
DNA proportion. QuASAR-MPRA results from each replicate were then combined using
the fixed effects method, and corrected for multiple tests using BH procedure (Benjamini
and Hochberg, 1995). The effect size βl,n of each replicate n is weighted by wn,l = 1/σ̂2n,l,
to calculate the overall effect size and standard error:
β∗l =
1
w∗l
∑
n
βn,l wn,l σ
∗
l =
√
1/w∗l (0.13)
where w∗l =
∑
nwn, l. We can then calculate the Z-score and p-value to test for an overall
change between all the RNA replicates combined with respect to the original DNA propor-
tion β0:
Zl =
β∗l − β0
σ∗l
, β0 = log
rl
1− rl
, p = 2Φ(−|Zl|) (0.14)
We used the genomic inflation test to calculate the genomic inflation parameter, λ, for a set
of p-values (Yang et al., 2011). For this we calculated the ratio of the median of the p-value
distribution to the expected median, thus quantifying the extent of the bulk inflation and
the excess false positive rate.
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BiT-BUNDLE-seq data analysis
Counts from both the unbound and bound DNA were combined, and a filter was set so
that each SNP direction combination had 5 counts for each allele. This combined count
was also used to calculate a reference proportion. Each replicate for the bound and un-
bound libraries were then run through QuASAR-MPRA using the calculated reference pro-
portion. These were then compared using ∆AST (Moyerbrailean et al., 2016a) to identify
ASB in the bound fraction that is differential relative to the unbound fraction. The repli-
cates were combined using Stouffer′s method (STOUFFER et al., 1949) to identify ASB for
each NFKB1 concentration, and combined again to identify the total ASB. The unbound
and bound libraries counts were additionally analyzed with DESeq2 (Love et al., 2014)
to identify over-represented bound enhancer regions (FDR 1% and logFC>1). To better
estimate the dispersion parameters, the DESeq2 model was fit on all sequencing data and
without merging the replicate libraries:
Kij ∼ NB(µij, αi) (0.15)
µij = sjqij (0.16)
log2(qij) = βi,0 + βi,C(j) + βi,B(j) (0.17)
For each enhancer region i and sample j, the read counts Kij are modeled using a nega-
tive binomial distribution with fitted mean µij and an enhancer region-specific dispersion
parameter αi. The fitted mean is composed of a sample-specific size factor sj and a pa-
rameter qij proportional to the expected true concentration of regions for sample j. The
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coefficient β0 represents the mean effect intercept, βC(j) represents the lane (NFKB1 con-
centration:replicate) effect, and and βB(j) represents the Bound/Unbound effect for each
NFKB1 concentration (High, Medium, and Low).
We then contrasted the bound to the unbound for each concentration (i.e., high con-
centration bound to high concentration unbound) using the default DESeq2 Wald test for
each enhancer region βB(j) 6== 0, and a Benjamini-Hochberg (BH) adjusted p-value was
calculated with automatic independent filtering (DESeq2 default setting).
GWAS overlap
SNPs nominally significant (p<0.05) for ASB (identified with ∆AST) or ASE (identified
with QuASAR-MPRA) that were also annotated as CentiSNP were overlapped with SNPs
from the GWAS catalogue (V6) (MacArthur et al., 2017), as well as with SNPs fine-mapped
with the fgwas software as in (Moyerbrailean et al., 2016b).
Table 14: BiT-STARR-seq results. QuASAR-MPRA results for BiT-STARR-seq.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S1. txt
Table 15: Annotations Used: CentiSNPs. SNP annotations used for overlap with BiT-BUNDLE-seq and BiT-STARR-seq. First 4 columns
are in the same order for each file (chr, pos, pos1, rsID). Column 5 contains the transcription factor with a CentiSNP at that location.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S2. txt
Table 16: Annotations Used: GWAS. SNP annotations used for overlap with BiT-BUNDLE-seq and BiT-STARR-seq. First 4 columns are
in the same order for each file (chr, pos, pos1, rsID). Column 5 contains the GWAS trait associated with the SNP.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S3. txt
Table 17: Annotations Used: eQTL. SNP annotations used for overlap with BiT-BUNDLE-seq and BiT-STARR-seq. First 4 columns are in
the same order for each file (chr, pos, pos1, rsID). eQTL SNPs. Column 5 contains the information for whether the eQTL was identified
in cells infected with L (Listeria), S (Salmonella), or NI (not infected). Column 6 contains the gene associated with the eQTL. Column
7 contains the beta for the eQTL association. Column 8 contains the p-value for the eQTL association.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S4. txt
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Table 18: Distribution of ASE Z-scores. For each regulatory category: KS-test results from comparing the Z-score distribution for ASE
for the category vs the negative control.
Reg Cat p-value
CentiSNPs 2.44× 10−6
ASH 4.28× 10−4
Liver_eQTLs 3.19× 10−4
LCL_eQTLs 0.01
fgwas_SNPs <2.20× 10−16
Table 19: Transcription factors in BiT-STARR-seq. Number of SNPs in motifs matching the top 10 covered transcription factors in
BiT-STARR-seq.
Transcription Factor Freq
CTCF 4911
E2F-1 2794
E2F 4407
ATF 5567
AML1 3794
ATF2:c-Jun 3651
CREB 12955
AP1 2673
ARG RI 3445
STF1 3561
Table 20: DEseq results: Combined concentrations. Differentially bound regions for combined concentrations. Columns are (identi-
fier(rsID_Direction), adjusted p-value, p-value, logFC).
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S7. txt
Table 21: DEseq results: Low concentration. Differentially bound regions for low concentration. Columns are (identi-
fier(rsID_Direction), adjusted p-value, p-value, logFC).
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S8. txt
Table 22: DEseq results: Mid. Differentially bound regions for mid concentration. Columns are (identifier(rsID_Direction), adjusted
p-value, p-value, logFC).
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S9. txt
Table 23: DEseq results: High. Differentially bound regions for high concentration. Columns are (identifier(rsID_Direction), adjusted
p-value, p-value, logFC).
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S10. txt
Table 24: BiT-BUNDLE-seq results. ∆AST results for BiT-BUNDLE-seq. Columns are identifier, Z-score, p-value, adjusted p-value, rsID.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S11. txt
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Table 25: Designed Regulatory Category Content. For each regulatory category: the number of constructs and how many were
significant (FDR 10%) for ASB.
Reg Cat Tested ASB ASB
ASH 180 4
CentiSNPs 50359 1514
fgwas_SNPs 5811 285
Negative_Control 1676 43
LCL_eQTLs 2753 73
Liver_eQTLs 29070 1009
Table 26: Enrichment for ASB and ASE variants in TFs. For each transcription factor: enrichment results from a Fisher′s test for ASE
in the category vs being in the TF, subset for having ASB.
TF OR p-value
AML1 4.61 0.01
CREB1 Inf 0.02
CTCF 2.86 0.07
CREB 1.31 0.35
ARG RI 1.37 0.58
STF1 1.26 0.83
E2F 0.98 0.84
ATF 0.94 0.86
AP1 1.21 1.00
ATF:c-Jun 1.10 1.00
Table 27: ASB and complex traits. ∆AST results for BiT-BUNDLE-seq. SNPs are nominally significant, associated to a complex trait,
and are also CentiSNPs. Columns are rsID, direction, p-value, complex trait.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S14. txt
Table 28: ASE and complex traits. QuASAR-MPRA results for BiT-STARR-seq. SNPs are nominally significant, associated to a complex
trait, and are also CentiSNPs. Columns are rsID, direction, p-value, complex trait.
Available at https: // genome. cshlp. org/ content/ suppl/ 2018/ 10/ 17/ gr. 237354.
118. DC1/ Supplemental_ Table_ S15. txt
Table 29: Designed Regulatory Category Content. For each regulatory category: the number of constructs and how many were
significant (FDR 10%) for ASE and enrichment results from a Fisher′s test for ASE in the category vs the negative control.
Reg Cat Tested ASE Sig ASE OR ASE p-value ASE
ASH 162 5 1.77 0.23
CentiSNPs 43615 1806 2.40 1.28× 10−5
fgwas_SNPs 4894 338 4.12 1.54× 10−13
Negative_Control 1111 20 NA NA
LCL_eQTLs 2307 94 2.36 2.41× 10−4
Liver_eQTLs 22943 827 2.08 4.88× 10−4
Table 30: Primers used in BiT-STARR-seq.
Primer Sequence
STARR_F_SH CCGAGCCCACGAGACCTAGAGTCGGGGCGGCCG
STARR_R_SH TGACGCTGCCGACGAAATTATTACACGGCGATC
F_transposase TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
R_transposase GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG
F_trans_short TCGTCGGCAGCGTCAGAT
I2.1 CAAGCAGAAGACGGCATACGA
Nextera_i7_10N CAAGCAGAAGACGGCATACGAGATRDHBVDHBVDGTCTCGTGGGCTCGG
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Table 31: Sequencing Depth. Sequencing depth for each BiT-STARR-seq replicate. Seq depth is total reads, and after deduplication is
the number of reads after removing duplicates using UMI tools.
Rep Seq Depth UMI Depth
Rep1 89,360,505 482,117
Rep2 55,819,932 182,865
Rep3 32,784,823 1,487,089
Rep4 34,141,541 577,343
Rep5 71,090,681 464,647
Rep6 36,835,814 987,771
Rep7 74,991,057 550,080
Rep8 61,014,562 640,360
Rep9 31,142,602 404,739
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Figure 27: Schematic of oligos in BiT-STARR-seq and BiT-BUNDLE-seq.
Figure 28: Correlation of DNA libraries. Scatterplot of filtered DNA library counts for each replicate plotted against all other replicates
in log10 scale. Spearman rho correlation range is stated at the top.
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Figure 29: Correlation of RNA libraries. Scatterplot of filtered RNA library counts for each replicate plotted against all other replicates
in log10 scale. Spearman rho correlation range is stated at the top.
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Figure 30: BiT-STARR-seq effect by regulatory category. Z-score distribution for SNPs in each designed regulatory category. Absolute
Z-score (y axis) for each regulatory category (x axis) is shown in the boxplot, center line of the boxplot is the median.
Figure 31: DNase window centering of BiT-STARR-seq variants. QQplot depicting the p-value distributions from QuASAR-MPRA
based on how far the regulatory variant is from the center of the DNase window.
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Figure 32: DNase peak size of BiT-STARR-seq variants. QQplot depicting the p-value distributions from QuASAR-MPRA based on the
DNase peak size.
Figure 33: Enrichment of NF-kB complex footprints in BiT-BUNDLE-seq bound regions. Fisher′s exact test was performed to identify
enrichment (x axis is the OR) for significant differentially bound regions (logFC>1 and FDR<1%). In red are the regions containing a
SNP in a NF-kB complex footprint, in blue the regions containing a SNP in footprints for other transcription factors.
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Figure 34: Overlap between constructs with significant ASB for each concentration in BiT-BUNDLE-seq. In purple are the number
ASB at low concentration, in yellow are the number ASB at mid concentration, and in blue are the number ASB at high concentration.
A B C D
Figure 35: Overlap between constructs with significant ASB or ASE. A) Overlap at 10% FDR. B) Overlap at 20% FDR. C) Overlap at
30% FDR. D) Overlap at nominal p-value (p-value<0.05).
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Figure 36: Depletion of ASE with TFs that repress NFKB1 binding. QQplot depicting the ASE p-value distribution from QuASAR-
MPRA for SNPs with CREB1 or AML1 binding (green) or not with CREB1 or AML1 binding (grey)
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Genome-wide association studies (GWAS) have identified a large number of genetic
variants associated with disease as well as normal phenotypic variation for complex traits.
However challenges remain in determining the functional relevance of human DNA se-
quence variants. Even after fine mapping, most variants are located in non-coding regions
making it difficult to infer mechanisms linking individual genetic variants with the disease
trait. In addition, we do not know under which environmental conditions the sequence
variants have a functional impact, and whether they become one of many factors involved
in complex phenotypes at the organismal level.
Chapter 1 describes computational methods to predict causal GWAS variants, valida-
tion of a subset for ASE using a traditional reporter assay, and development of a method
to identify ASE in high throughput assays. These methods improved positive detection of
enhancer activity and ASE, and this analysis pipeline will continue to be useful as more
researchers begin using high throughput assays to identify allelic effects. Chapter 2 im-
proves upon chapter 1 with the development of a new modification of STARR-seq in order
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to streamline the assay and improve power to detect ASE through the addition of an UMI.
Additionally, by integrating BiT-STARR-seq with a high throughput allele-specific EMSA,
we are able to identify the mechanism behind many ASE variants.
Studying GxE in human studies is extremely difficult, so our approach of using an
in-vitro method and modeling molecular phenotypes is a useful alternative. Chapter 3
describes the investigation of GxE with complex traits. Using GEMMA, we were able to
identify environments that were enriched for complex traits. With ATAC-seq data we were
able to identify differentially accessible regions, TF footprints, and differential TF foot-
prints. Integrating this data with BiT-STARR-seq, we were able to identify enrichment for
these differential chromatin accessibility regions with ASE.
Overall, these chapters show the integration of computational predictions with exper-
imental validation in order to identify allelic effects. This design is a useful approach to
validate the molecular mechanism for specic transcription factors, and link these to the
context of human health.
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